AMINO-TRIAZOLOPYRIDINE DERIVATIVES

Abstract: The invention relates to compounds of formula (I) wherein R<1> is a 5 or 6 membered heteroaryl group, containing 1 to 3 heteroatoms, selected from N, O or S, and which groups are optionally substituted by one or two substituents, which are lower alkyl, -(CH2)nOH, halogen or lower alkoxy, and wherein the heteroaryl groups may be optionally linked to the pyrazole ring via an alkylene or alkenyle group, or is phenyl, optionally substituted by one or two substituents being lower alkyl, hydroxy-lower alkyl, halogen, hydroxy or lower alkoxy or is -O(CH2)nphenyl, benzofuryl, indolyl or benzothiophenyl, or is -S-lower alkyl; R<2> and R<4> are independently from each other hydrogen, cyano or -S(O)2-phenyl; R<3> is hydrogen, halogen or is a 5 or 6 membered heteroaryl group, containing 1 to 3 heteroatoms, selected from N, O or S, and which groups are optionally substituted by one or two substituents, which are lower alkyl, -(CH2)n-aryl, hydroxy, halogen, lower alkoxy, morpholinyl, amino, lower alkylamino or -C(O)NR'2, and wherein R' is lower alkyl or hydrogen, or is phenyl, optionally substituted by one or two substituents being halogen, lower alkyl, lower alkoxy, amino, di-lower alkyl amino, CF3, -OCF3, -NHC(O)lower alkyl, cyano, -C(O)-lower alkyl, -C(O)O-lower alkyl, -S-lower alkyl, -S(O)2NH-phenyl, -S(O)2-methylpiperazinyl; or is -NR'R", wherein R' and R" are independently from each other hydrogen, -(CH2)nphenyl, which phenyl ring is optionally substituted hy halogen or lower alkoxy, -CH(lower alkyl)-phenyl, indan-l-yl,1,2,3,4-tetrahydro-naphthalen, or cycloalkyl; or is -O-phenyl, which phenyl ring is optionally substituted by halogen, lower alkyl or lower alkoxy, -O-tetrahydronaphthalenyl or -O-CH2-6-methyl-pyridin-2-yl; or is -benzo[1,3]dioxolyl, -1H-indol-5,-yl, naphthyl, benzofuran-2-yl, 1,3,4,9-tetrahydro-b-carbolin-2-yl, piperidin-1-yl, pyrrolidin-1-yl, piperazin-4-yl-methyl or morpholinyl; R<5> is -NR2, wherein R may be the same or different and is hydrogen, lower alkyl, phenyl, benzyl, -CO-lower alkyl, -CO-lower alkoxy, -lower alkenyl, -CO(CH2)n-phenyl or -COO(CH2)n-phenyl, wherein the phenyl ring is optionally subsituted by CF3, lower alkoxy, halogen or lower alkyl, -CO(CH2)3-NHCO-lower alkoxy, -(CH2)n-phenyl, wherein the phenyl ring is optionally substituted by lower alkoxy, CF3 or halogen, or is 4,5-dihydro-1H-imidazol-2-yl-benzoic acid, 1,4,5,6-tetrahydro-pyrimidin-2-yl-benzoic acid or 4,5,6,7-tetrahydro-1H-[1,3]diazepeinn-2-yl-benzoic acid; n is 0-4 and their pharmaceutically acceptable salts.

Description: Amino- triazolopyr id ine derivatives The present invention relates to compounds of the general formula wherein R 1 is a 5 or 6 membered heteroaryl group, containing 1 to 3 heteroatoms, selected from N, O or S, and which groups are optionally substituted by one or two substituents, which are lower alkyl, -(CH 2 ) n OH, halogen or lower alkoxy, and wherein the heteroaryl groups may be optionally linked to the pyrazole ring via an alkylene or alkenyle group, or is phenyl, optionally substituted by one or two substituents being lower alkyl, hydroxy-lower alkyl, halogen, hydroxy or lower alkoxy or is -O(CH 2 ) n phenyl, benzofuryl, indolyl or benzothiophenyl, or is -S-lower alkyl; R 2 and R 4 are independently from each other hydrogen, cyano or -S(O) 2 -phenyl; R" is hydrogen, halogen or is a 5 or 6 membered heteroaryl group, containing 1 to 3 heteroatoms, selected from N, O or S, and which groups are optionally substituted by one or two substituents, which are lower alkyl, -(CH 2 ) n -aryl, hydroxy, halogen, lower alkoxy, morphohnyl, amino, lower alkylamino or -C(O)NR' ) and wherein R' is lower alkyl or hydrogen, or is phenyl, optionally substituted by one or two substituents being halogen, lower alkyl, lower alkoxy, amino, di-lower alkyl amino, CF 3 , -OCF 3 , -NHC(O)lower alkyl, cyano, -C(O)-lower alkyl, -C(O)O-lower alkyl, -S-lower alkyl, -S(O) 2 NH-phenyl, -S(O) -methylpiperazinyl; or is -NR'R", wherein R' and R" are independently from each other hydrogen, -(CH 2 ) n phenyl, which phenyl ring is optionally substituted by halogen or lower alkoxy, -CH(lower alkyl) -phenyl, indan-1-yl, 1,2,3,4-tetrahydro-naphthalen, or cycloalkyl; or is -O-phenyl, which phenyl ring is optionally substituted by halogen, lower alkyl or lower alkoxy, -O-tetrahydronaphthalenyl or -O-CH 2 -6-methyl-pyridin-2-yl; or is -benzo[l,3]dioxolyl, -lH-indol-5-yl, naphthyl, benzofuran-2-yl, l,3,4,9-tetrahydro-b-carbolin-2-yl, piperidin-1-yl, pyrrolidin-1-yl, piperazin-4-yl-methyl or morphohnyl; R 5 is -NR 2 , wherein R may be the same or different and is hydrogen, lower alkyl, phenyl, benzyl, -CO-lower alkyl, -CO-lower alkoxy, -lower alkenyl, -CO(CH 2 ) n -phenyl or -COO(CH 2 ) n -phenyl, wherein the phenyl ring is optionally substituted by CF 3 , lower alkoxy, halogen or lower alkyl, -CO(CH 2 ) 3 -NHCO-lower alkoxy, -(CH 2 ) n -phenyl, wherein the phenyl ring is optionally substituted by lower alkoxy, CF 3 or halogen, or is 4,5-dihydro-lH-imidazol-2-yl-benzoic acid, l,4,5,6-tetrahydro-pyrimidin-2-yl-benzoic acid or 4,5,6,7-tetrahydro- IH- [ l,3]diazepin-2-yl-benzoic acid; n is 0 - 4 and to their pharmaceutically acceptable salts. It has surprisingly been found that the compounds of general formula I are adenosine receptor ligands. Adenosine modulates a wide range of physiological functions by interacting with specific cell surface receptors. The potential of adenosine receptors as drug targets was first reviewed in 1982. Adenosine is related both structurally and metabolically to the bioactive nucleotides adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP) and cyclic adenosine monophosphate (cAMP); to the biochemical methylating agent S-adenosyl-L-methione (SAM); and structurally to the coenzymes NAD, FAD and coenzym A; and to RNA. Together adenosine and these related compounds are important in the regulation of many aspects of cellular metabolism and in the modulation of different central nervous system activities. The receptores for adenosine have been classified as A i} A 2A , A 2 B and A 3 receptors, belonging to the family of G protein-coupled receptors. Activation of adenosine receptors by adenosine initiates signal transduction mechanism. These mechanisms are dependent on the receptor associated G protein. Each of the adenosine receptor subtyps has been classically characterised by the adenylate cyclase effector system, which utilises cAMP as a second messenger. The Ai and A 3 receptors, coupled with G; proteins inhibit adenylate cyclase, leading to a decrease in cellular cAMP levels, while A 2A and A 2B receptors couple to G s proteins and activate adenylate cyclase, leading to an increase in cellular cAMP levels. It is known that the Ai receptor system include the activation of phospholipase C and modulation of both potassium and calcium ion channels. The A 3 subtype, in addition to its association with adenylate cyclase, also stimulates phospholipase C and so activates calcium ion channels. The Ai receptor (326-328 amino acids) was cloned from various species (canine, human, rat, dog, chick, bovine, guinea-pig) with 90-95% sequence identify among the mammalian species. The A 2A receptor (409-412 amino acids) was cloned from canine, rat, human, guinea pig and mouse. The A B receptor (332 amino acids) was cloned from human and mouse with 45% homology of human A 2 B with human A! and A 2A receptors. The A 3 receptor (317-320 amino acids) was cloned from human, rat, dog, rabbit and sheep. The Ai and A IA. receptor subtypes are proposed to play complementary roles in adenosine's regulation of the energy supply. Adenosine, which is a metabolic product of ATP, diffuses from the cell and acts locally to activate adenosine receptors to decrease the oxygen demand (Ai) or increase the oxygen supply (A 2A ) and so reinstate the balance of energy supply: demand within the tissue. The actions of both subtyps is to increase the amount of available oxygen to tissue and to protect cells against damage caused by a short term imbalance of oxygen. One of the important functions of endogenous adenosine is preventing damage during traumas such as hypoxia, ischaemia, hypotension and seizure activity. Furthermore, it is known that the binding of the adenosine receptor agonist to mast cells expressing the rat A 3 receptor resulted in increased inositol triphosphate and intracellular calcium concentrations, which potentiated antigen induced secretion of inflammatory mediators. Therefore, the A 3 receptor plays a role in mediating asthmatic attacks and other allergic responses. Adenosine is also a neuromodulator, possessing global importance in the modulation of molecular mechanisms underlying many aspects of physiological brain function by mediating central inhibitory effects. An increase in neurotransmitter release follows traumas such as hypoxia, ischaemia and seizures. These neurotransmitters are ultimately responsible for neural degeneration and neural death, which causes brain damage or death of the individual. The adenosine Ai agonists which mimic the central inhibitory effects of adenosine may therefore be useful as neuroprotective agents. Adenosine has been proposed as an endogenous anticonvulsant agent, inhibiting glutamate release from excitory neurons and inhibiting neuronal firing. Adenosine agonists therefore may be used as antiepileptic agents. Adenosine antagonists stimulate the activity of the CNS and have proven to be effective as cognition enhancers. Selective A 2a -antagonists have therapeutic potential in the treatment of various forms of dementia, for example in Alzheimer's disease and are useful as neuroprotective agents. Adenosine A 2 - receptor antagonists inhibit the release of dopamine from central synaptic terminals and reduce locomotor activity and consequently improve Parkinsonian symptoms. The central activities of adenosine are also implicated in the molecular mechanism underlying sedation, hypnosis, schizophrenia, anxiety, pain, respiration, depression and substance abuse. Drugs acting at adenosine receptors therefore have also therapeutic potential as sedatives, muscle relaxants, antipsychotics, anxiolytics, analgesics, respiratory stimulants and antidepressants. An important role for adenosine in the cardiovascular system is as a cardioprotective agent. Levels of endogenous adenosine increase in response to ischaemia and hypoxia, and protect cardiac tissue during and after trauma (preconditioning). Adenosine agonists thus have potential as cardioprotective agents. Adenosine modulates many aspects of renal function, including renin release, glomerular filtration rate and renal blood flow. Compounds, which antagonise the renal affects of adenosine, have potential as renal protective agents. Furthermore, adenosine A 3 and/ or A 2B antagonists may be useful in the treatment of asthma and other allergic responses. Numerous documents describe the current knowledge on adenosine receptors, for example the following publications: Bioorganic & Medicinal Chemistry, 6, (1998), 619-641, Bioorganic & Medicinal Chemistry, 6, (1998), 707-719, J. Med. Chem., (1998), 41, 2835-2845, J. Med. Chem., (1998), 41, 3186-3201, J. Med. Chem., (1998), 41, 2126-2133, J. Med. Chem., (1999), 42, 706-721, J. Med. Chem., (1996), 39, 1164-1171, Arch. Pharm. Med. Chem., 332, 39-41, (1999) Objects of the present invention are compounds of formula I and their pharmaceutically acceptable salts per se and as pharmaceutically active substances, their manufacture, medicaments based on a compound in accordance with the invention and their production as well as the use of compounds of formula I in the control or prevention of illnesses based on the modulation of the adenosine system, such as Alzheimer's disease, Parkinson's disease, neuroprotection, schizophrenia, anxiety, pain, respiration deficits, depression, asthma, allergic responses, hypoxia, ischaemia, seizure and substance abuse. Furthermore, compounds of the present invention may be useful as sedatives, muscle relaxants, antipsychotics, antiepileptics, anticonvulsants and cardiaprotective agents.The most preferred indications in accordance with the present invention are those, which base on the A^ receptor antagonistic activity and which include disorders of the central nervous system, for example the treatment or prevention of certain depressive disorders, neuroprotection and Parkinson's disease. As used herein, the term "lower alkyl" denotes a saturated straight- or branched- chain alkyl group containing from 1 to 6 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, n-butyl, i-butyl, 2-butyl, t-butyl and the like. Preferred lower alkyl groups are groups with 1 - 4 carbon atoms. As used herein, the term "lower alkenyl" denotes a unsaturated straight- or branched- chain alkyl group containing from 2 to 6 carbon atoms, for example, ethylen, propylen, isopropylen, n-butylen, i-butylen, 2-butylen, t-butylen and the like. Preferred lower alkyl groups are groups with 2 - 4 carbon atoms. The term "cycloalkyl" denotes a saturated carbocyclic group, containing 3 - 6 carbon atoms. The term "halogen" denotes chlorine, iodine, fluorine and bromine. The term "lower alkoxy" denotes a group wherein the alkyl residues is as defined above, and which is attached via an oxygen atom. The term "5 or 6 membered heteroaryl group" denotes, for example furyl, thiophenyl, thiazolyl, pyridinyl, tetrahydro-furanyl, 5,6-dihydro-4H-pyran-2-yl, isoxazol- 5-yl, 4,5-dihydro-furan-2-yl, 5,6-dihydro-pyran-2-yl, pyrazol-1-yl, 1,2,4-triazol-l-yl, imidazol-1-yl and the like. Preferred "aryl" groups are, for example phenyl or naphthyl groups. The term "pharmaceutically acceptable acid addition salts" embraces salts with inorganic and organic acids, such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methane-sulfonic acid, p-toluenesulfonic acid and the like. Exemplary preferred compounds, showing activity on the A A receptor, are compounds of formula I, wherein R 5 is an unsubstituted amino group and R 1 is furyl, for example the following compounds: 2-furan-2-yl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 2-furan-2-yl-7-pyridin-3-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 2-furan-2-yl-7-pyridin-2-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 7-(3,5-bis-trifluoromethyl-phenyl)-2-furan-2-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 7-(3,5-dichloro-phenyl)-2-furan-2-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 7-(4-chloro-phenyl)-2-furan-2-yl-[ 1,2,4] triazolo[l,5-a]pyridin-5-ylamine, 2-furan-2-yl-7-(2-methyl-pyridin-4-yl)-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 7-(2-ethyl-pyridin-4-yl)-2-furan-2-yl-[ 1,2,4] triazolo[l,5-a]pyridin-5-ylamine, 2-furan-2-yl-7-(2-propyl-pyridin-4-yl)- [ l,2,4]triazolo[ l,5-a]pyτidin-5-ylamine, 2-furan-2-yl-7-(2-isopropyl-pyridin-4-yl)-[ 1,2,4] triazolo[l,5-a]pyridin-5-ylamine, 7-(4-fluoro-phenyl)-2-furan-2-yl-[ 1,2,4] triazolo[l,5-a]pyridin-5-ylamine, 2-furan-2-yl-7-(l-oxy-pyridin-4-yl)-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 5-amino-2-furan-2-yl-7-pyridin-4-yl-[ 1,2,4] triazolo[l,5-a]pyridine-6-carbonitrile, 7-(3-amino-phenyl)-2-furan-2-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 7-(3,4-dimethoxy-phenyl)-2-furan-2-yl-[ 1,2,4] triazolo[l,5-a]pyridin-5-ylamine, 7-(3,4-dichloro-phenyl)-2-furan-2-yl-[ 1,2,4] triazolo[l,5-a]pyridin-5-ylamine, 7-(3-fluoro-phenyl)-2-furan-2-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, l-[3-(5-amino-2-furan-2-yl-[l,2,4]triazolo[l,5-a]pyridin-7-yl)-phenyl]-ethanone, 7-(2-fluoro-phenyl)-2-furan-2-yl-[ 1,2,4] triazolo[l,5-a]pyridin-5-ylamine, 2-furan-2-yl-7-m-tolyl-[ 1,2,4] triazolo[l,5-a]pyridin-5-ylamine, 2-furan-2-yl-7-(4-methylsulfanyl-phenyl)-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 2-furan-2-yl-7-thiophen-3-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 2-furan-2-yl-7-(3-trifluoromethyl-phenyl)-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 2-furan-2-yl-7-(3-methoxy-phenyl)-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, N-[3-(5-amino-2-furan-2-yl-[ 1,2,4] triazolo[l,5-a]pyridin-7-yl)-phenyl]-acetamide, 2-furan-2-yl-7-(lH-indol-5-yl)-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, N-[4-(5-amino-2-furan-2-yl-[l,2,4]triazolo[l,5-a]pyridin-7-yl)-2-methyl-phenyl]- acetamide, 2-furan-2-yl-7-piperidin-l-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 2-furan-2-yl-7-pyrrolidin- 1-yl- [ 1,2,4] triazolo [ l,5-a]pyridin-5-ylamine, 2-furan-2-yl-7-(4-methyl-piperazin-l-yl)-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, N7-(2-chloro-benzyl)-2-furan-2-yl-[ 1,2,4] triazolo[l,5-a]pyridine-5,7-diamine, 2-furan-2-yl-N7-(2-methoxy-benzyl)-[l,2,4]triazolo[l,5-a]pyridine-5,7-diamine, 2-furan-2-yl-N7-(l-phenyl-ethyl)-[l,2,4]triazolo[l,5-a]pyridine-5,7-diamine, 7-(5-butyl-pyridin-2-yl)-2-furan-2-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 7-(2-fluoro-pyridin-4-yl)-2-furan-2-yl-[ l,2,4]triazolo[ l,5-a]pyridin-5-ylamine, 7-(5-chloro-pyridin-2-yl)-2-furan-2-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine or 2-furan-2-yl-7-(6-methoxy-pyridin-3-yl)-[ 1,2,4] triazolo[l,5-a]pyridin-5-ylamine. Further preferred compounds are those, wherein R 5 is an unsubstituted amino group and R 1 is methyl substituted furyl, for example the following compounds: 7-(4-chloro-phenyl)-2-(5-methyl-furan-2-yl)-[ 1,2,4] triazolo[l,5-a]pyridin-5-ylamine, 7-(3-methoxy-phenyl)-2-(5-methyl-furan-2-yl)-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 7-(3,4-dimethoxy-phenyl)-2-(5-methyl-furan-2-yl)-[ 1,2,4] triazolo[l,5-a]pyridin-5- ylamine, N-{3-[5-amino-2-(5-methyl-furan-2-yl)-[l,2,4]triazolo[l,5-a]pyridin-7-yl]-phenyl}- acetamide or N-{4-[5-amino-2-(5-methyl-furan-2-yl)-[ 1,2,4] triazolo[l,5-a]pyridin-7-yl]-phenyl}- acetamide. Further preferred compounds are those, wherein R 5 is an unsubstituted amino group and R 1 is pyridin-2-yl, for example the following compounds: 7-(4-fluoro-phenyl)-2-pyridin-2-yl- [ 1,2,4] triazolo[ l,5-a]pyridin-5-ylamine, 7-(3-methoxy-phenyl)-2-pyridin-2-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 7-(3-amino-phenyl)-2-pyridin-2-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 7-(2-ethyl-pyridin-4-yl)-2-pyridin-2-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 7-(2-methyl-pyridin-4-yl)-2-pyridin-2-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 7-(5-ethyl-pyridin-2-yl)-2-pyridin-2-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 2,7-di-pyτidin-2-yl-[ 1,2,4] triazolo[l,5-a]pyridin-5-ylamine, 7-(5-chloro-pyridin-2-yl)-2-pyridin-2-yl- [ 1,2,4] triazolo[l,5-a]pyridin-5-ylamine or 7-(6-cUoro-pyridin-2-yl)-2-pyridin-2-yl-[l,2,4]triazolo[l,5-a]pyτidin-5-ylamine. Preferred compounds are further those, wherein R is an unsubstituted amino group and R 1 is 5,6-dihydro-furan-2-yl, for example the following compounds: 7-(3,4-dichloro-phenyl)-2-(4,5-dihydro-furan-2-yl)-[ 1,2,4] triazolo[l,5-a]pyridin-5- ylamine, 2-(4,5-dihydro-furan-2-yl)-7-(3-fluoro-phenyl)-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 2-(4,5-dihydro-furan-2-yl)-7-(4-fluoro-phenyl)-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 2-(4,5-dihydro-furan-2-yl)-7-m-tolyl-[ l,2,4]triazolo[ l,5-a]pyridin-5-ylamine or 2-(4,5-dihydro-furan-2-yl)-7-(3-trifluoromethyl-phenyl)-[l,2,4]triazolo[l,5-a]pyridin-5- ylamine. Preferred compounds are further those, wherein R 5 is an unsubstituted amino group and R 1 is pyrazol-1-yl, for example the following compound: 2-pyrazol-l-yl-7-pyridin-2-yl-[ 1,2,4] triazolo[l,5-a]pyridin-5-ylamine. Exemplary preferred compounds are those, wherein R 5 is a substituted amino group, and R 1 is phenyl, for example the following compounds: but-3-enyl-(2-phenyl-7-pyridin-4-yl-[ 1,2,4] triazolo[l,5-a]pyridin-5-yl)-amine, ethyl-(2-phenyl-7-pyridin-4-yl-[ 1,2,4] triazolo[l,5-a]pyridin-5-yl)-amine, (2-phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin-5-yl)-carbamic acid ethyl ester, N- (2-phenyl-7-pyridin-4-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-yl)-4-trifluoromethyl- benzamide, 2-(2-chloro-phenyl)-N-(2-phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin-5-yl)- acetamide, 2-(2,4-dichloro-phenyl)-N-(2-phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin-5-yl)- acetamide, N-(2-phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin-5-yl)-2-(2-trifluoromethyl- phenyl) -acetamide, N-(2-phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin-5-yl)-2-(4-trifluoromethyl- phenyl) -acetamide, 3-phenyl-N-(2-phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin-5-yl)-propionamide, N-(2-phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin-5-yl)-2-o-tolyl-acetamide, 2-(2-bromo-phenyl)-N-(2-phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin-5-yl)- acetamide, 2-(2-iodo-phenyl)-N-(2-phenyl-7-pyridin-4-yl-[ 1,2,4] triazolo [ 1,5-a] pyridin-5-yl)- acetamide, 3-(2-phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylcarbamoyl)-propyl]- carbamic acid tert-butyl ester, 2-(2-chloro-phenyl)-ethyl] -(2-phenyl-7-pyridin-4-yl- [ 1,2,4] triazolo [ l,5-a]pyridin-5-yl)- amine, 2-(2,4-dichloro-phenyl)-ethyl] -(2-phenyl-7-pyridin-4-yl- [ l,2,4]triazolo[ l,5-a]pyridin-5- yl) -amine, (2-phenyl-7-pyridin-4-yl- [ 1 ,2,4] triazolo [ 1 ,5-a]pyridin-5-yl)-(4-trifluoromethyl-benzyl)- amine, (3-phenyl-propyl)-(2-phenyl-7-pyri din-4-yl-[ 1,2,4] triazolo [l,5-a]pyridin-5-yl)-amine or diethyl- (2-phenyl-7-pyridin-4-yl-[ 1,2,4] triazolo [ 1,5-a] pyridin-5-yl)-amine. The present compounds of formula I and their pharmaceutically acceptable salts can be prepared by methods known in the art, for example, by processes described below, which process comprises a) reacting a compound of formula with a compound of formula to a compound of formula wherein R 1 - R 4 have the significances given above, or b) substituting one or two hydrogen atoms of the amino group in formula I-l by R, which is lower alkyl, phenyl, benzyl, -CO-lower alkyl, -CO-lower alkoxy, -lower alkenyl, - CO(CH 2 ) n -phenyl or -COO(CH 2 ) n -phenyl, wherein the phenyl ring is optionally substituted by CF 3 , lower alkoxy, halogen or lower alkyl, -CO(CH 2 ) 3 -NHCO-lower alkoxy, -(CH 2 ) n -phenyl, wherein the phenyl ring is optionally substituted by lower alkoxy, CF 3 or halogen. c) reacting a compound of formula with a compound of formula R 3 B(OH) 2 V to a compound of formula I-l, wherein R - R have the significances given above, or d) modifying one or more substituents R 1 - R 5 within the definitions given above, and if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts. In accordance with process variant a) to a boiling suspension of sodiumhydride and THF is added a mixture of compounds of formula II and III, for example 3- benzenesulfonylmethyl-5-furan-2-yl-lH- [ 1,2,4] triazole and 3-(4-pyridinyl)-2- propenenitrile or 3-benzenesulfonylmethyl-5-furan-2-yl-lH-[ 1,2,4] triazole and (E)-3-(2- methyl-pyridin-4-yl)-acrylonitril. The reaction is carried out at boiling temperature. The substitution of one or two hydrogen atoms of the amino group in formula I-l by R, wherein R has the significance given above, is carried out by conventional methods, for example with corresponding acetyl- or benzoyl chlorides. A further method for the preparation of compounds of formula I is described in process variant c). In accordance with this method, a mixture of a compound of formula IV, for example 7-bromo-2-phenyl-[ 1,2,4] pyridin-5-ylamine and of a compound of formula V, for example p-tolyl-boronic acid, is treated with tetrakis- (triphenylphosphine)palladium and heated to about 90°C. The reaction is carried out in the presence of a base, for example in Na 2 CO 3 , Cs 2 CO 3 or triethylamine. The salt formation is effected at room temperatures in accordance with methods which are known per se and which are familiar to any person skilled in the art. Not only salts with inorganic acids, but also salts with organic acids came into consideration. Hydrochlorides, hydrobromides, sulphates, nitrates, citrate, acetates, maleates, succinates, methan-sulphonates, p-toluenesulphonates and the like are examples of such salts. In Examples 1 - 351 and in the following schemes 1 and 2 the preparation of compounds of formula I is described in more detail. The starting materials of formulae III, V, VI, VIII and X are known compounds or maybe prepared according to methods known in the art. Scheme 1 EtOH/HCI 1.1NNaOH dioxane, rt THF, NaH, reflux The meaning of the substituents R -R is given above Scheme 2 XIV The compounds of formula I and their pharmaceutically usable addition salts possess valuable pharmacological properties. Specifically, it has been found that the compounds of the present invention are adenosine receptor ligands. The compounds were investigated in accordance with the tests given hereinafter. Human adenosine A 2A receptor The human adenosine A 2A receptor was recombinantly expressed in Chinese hamster ovary (CHO) cells using the semliki forest virus expression system. Cells were harvested, washed twice by centrifugation, homogenised and again washed by centrifugation. The final washed membrane pellet was suspended in a Tris (50mM) buffer containing 120mM NaCl, 5mM KCl, 2mM CaCl 2 and lOmM MgCl 2 (pH 7.4) (buffer A). The [ 3 H]-SCH-58261 (Dionisotti et al., 1997, Br J Pharmacol 121, 353; InM) binding assay was carried out in 96- well plates in the presence of 2.5μg of membrane protein, 0.5mg of Ysi-poly-1-lysine SPA beads and 0.1U adenosine deaminase in a final volume of 200μl of buffer A. Non-specific binding was defined using xanthine amine congener (XAC; 2μM). Compounds were tested at 10 concentrations from 10μM-0.3nM. All assays were conducted in duplicate and repeated at least two times. Assay plates were incubated for lhour at room temperature before centrifugation and then bound ligand determined using a Packard Topcount scintillation counter. IC 50 values were calculated using a non-linear curve fitting program and Ki values calculated using the Cheng-Prussoff equation. In accordance with the invention, it has been shown that compounds of formula I have a high affinity toward the A 2A receptor. The preferred compounds have an pKi value in the range of 7.5 to 8.4 in the human A 2A binding. In the table below are described some specific pKi values of preferred compounds. The compounds of formula I and the pharmaceutically acceptable salts of the compounds of formula I can be used as medicaments, e.g. in the form of pharmaceutical preparations. The pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions. The administration can, however, also be effected rectally, e.g. in the form of suppositories, parenterally, e.g. in the form of injection solutions. The compounds of formula I can be processed with pharmaceutically inert, inorganic or organic carriers for the production of pharmaceutical preparations. Lactose, corn starch or derivatives thereof, talc, stearic acids or its salts and the like can be used, for example, as such carriers for tablets, coated tablets, dragees and hard gelatine capsules. Suitable carriers for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like. Depending on the nature of the active substance no carriers are, however, usually required in the case of soft gelatine capsules. Suitable carriers for the production of solutions and syrups are, for example, water, polyols, glycerol, vegetable oil and the like. Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like. The pharmaceutical preparations can, moreover, contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances. Medicaments containing a compound of formula I or a pharmaceutically acceptable salt thereof and a therapeutically inert carrier are also an object of the present invention, as is a process for their production, which comprises bringing one or more compounds of formula I and/or pharmaceutically acceptable acid addition salts and, if desired, one or more other therapeutically valuable substances into a galenical administration form together with one or more therapeutically inert carriers. In accordance with the invention compounds of formula I as well as their pharmaceutically acceptable salts are useful in the control or prevention of illnesses based on the adenosine receptor antagonistic activity, such as Alzheimer's disease, Parkinson's disease, neuroprotection, schizophrenia, anxiety, pain, respiration deficits, depression, asthma, allergic responses, hypoxia, ischaemia, seizure and substance abuse. Furthermore, compounds of the present invention may be useful as sedatives, muscle relaxants, antipsychotics, antiepileptics, anticonvulsants and cardiaprotective agents and for the production of corresponding medicaments. The most preferred indications in accordance with the present invention are those, which include disorders of the central nervous system, for example the treatment or prevention of certain depressive disorders, neuroprotection and Parkinson's disease. The dosage can vary within wide limits and will, of course, have to be adjusted to the individual requirements in each particular case. In the case of oral administration the dosage for adults can vary from about 0.01 mg to about 1000 mg per day of a compound of general formula I or of the corresponding amount of a pharmaceutically acceptable salt thereof. The daily dosage may be administered as single dose or in divided doses and, in addition, the upper limit can also be exceeded when this is found to be indicated. Tablet Formulation (Wet Granulation) Item Ingredients mg/tablet 5 mg 25 J mg 100 mg 500 mg 1. Compound of formula I 5 25 100 500 2. Lactose Anhydrous DTG 125 105 30 150 3. Sta-Rx 1500 6 6 6 30 4. Microcrystalline Cellulose 30 30 30 150 5. Magnesium Stearate 1 1 1 1 Total 167 167 167 831 Manufacturing Procedure 1. Mix items 1, 2, 3 and 4 and granulate with purified water. 2. Dry the granules at 50°C. 3. Pass the granules through suitable milling equipment. 4. Add item 5 and mix for three minutes; compress on a suitable press. Capsule Formulation Item Ingredients m g/capsule 5 ] mg 25 ) mg 100 mg 500 mg 1. Compound of formula I 5 25 100 500 2. Hydrous Lactose 159 123 148 — 3. Corn Starch 25 35 40 70 4. Talc 10 15 10 25 5. Magnesium Stearate 1 2 2 5 Total 200 200 300 600 Manufacturing Procedure 1. Mix items 1, 2 and 3 in a suitable mixer for 30 minutes. 2. Add items 4 and 5 and mix for 3 minutes. 3. Fill into a suitable capsule. Example 1 2-Furan-2-yl-7-pyridin-4-yl- [ 1 ,2,4] triazolo [ 1,5-a] pyridin-5-ylamine a) Furan-2-carboxylic acid (l-amino-2-benzenesulfonyI-ethylidene)-hydrazide A suspension of 85.0g (0.32mol) 2-(phenylsulfonyl)-ethanimidic acid ethyl ester hydrochloride in 700 ml chloroform was treated with 320 ml IN aqueous sodium hydoxide. 100 ml of a saturated aqueous sodiumbicarbonate solution was added and the mixture was extracted with chloroform. The extracts were combined and dried with sodium sulfate and the solvents were distilled off under reduced pressure. The resulting colorless oil was stirred together with 42.6g (0.34mol) 2-furancarboxylic acid hydrazide in 600ml chloroform for 24 hours at 50°C. The resulting precipitate was filtered off and dried. A quantitative yield of furan-2-carboxylic acid (l-amino-2-benzenesulfonyl-ethylidene)- hydrazide was obtained as pale crystals, mp. 195°C (decomposition), MS m/e (%): 308 (M+H + , 100). b 3-Benzenesulfonylmethyl-5-furan-2-yl-lH- [ 1,2,4] triazole 105g (0.34mol) Furan-2-carboxylic acid (l-amino-2-benzenesulfonyl-ethylidene)- hydrazide were heated at 200°C for 20 minutes. The molten mass was then cooled, dissolved in 250 ml hot ethanol and stirred overnight at room temperature. The precipitated crystals were filtered off and dried to yield 65.7 g (66%) 3- benzenesulfonylmethyl-5-furan-2-yl-lH-[ 1,2,4] triazole as white crystals with mp. 185- 186°C, MS m/e (%): 290 (M+H + , 100). c) 2-Furan-2-yl-7-pyridin-4-yl-[ 1,2,4] triazolo [ 1,5-a] pyridin-5-ylamine To a boiling suspension of 5.9g(0.12mol) sodiumhydride (55%) in 100 ml tetrahydrofuran was slowly added over a period of 6 hours a mixture of 10. lg (0.035mol) 3- benzenesulfonylmethyl-5-furan-2-yl-lH-[l,2,4]triazole and 4.56g (0.035mol) 3-(4- pyridinyl)-2-propenenitrile in 400 ml tetrahydrofuran. Boiling was continued for 15 hours and then 50ml methanol were added at room temperature. Evaporation of the solvent and chromatography on silicagel with dichloromethane/methanol 95/5 gave 1.3g (13%) 2- furan-2-yl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine as yellow crystals with mp. 294-296°C. Example 2 2-Furan-2-yl-7-pyridin-3-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-ylamine The title compound, MS m/e (%): 277 (M + , 100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-furan-2-yl-lH- [1,2,4] triazole and 3-(3-pyridinyl)-2-propenenitrile. Example 3 2-Furan-2-yl-7-pyridin-2-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-ylamine The title compound, MS m/e (%): 278 (M+H + , 100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-furan-2-yl-lH- [1,2,4] triazole and 3-(2-pyτidinyl)-2-propenenitrile. Example 4 7- (3,5-Bis-trifluoromethyl-phenyl)-2-furan-2-yl- [ 1 ,2,4] triazolo [1,5-a] pyridin-5-ylamine The title compound, MS m/e (%): 412 (M + , 100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-furan-2-yl-lH- [ 1,2,4] triazole and 3-[3,5-bis(trifluoromethyl)phenyl]acrylonitrile. Example 5 7- (3,5-Dichloro-phenyl)-2-furan-2-yl- [ 1 ,2,4] triazolo [1,5-a] pyridin-5-ylamine a) Mixture of (E)- and (Z)-3-(3,5-dic oro-phenyl)-acrylonitrile To a suspension of 0.68g (0.024mol) sodiumhydride in 20 ml tetrahydrofiirane and 20 ml dimethylformamide were added 5.79g (0.017mol) (cyanomethyl)triphenylphosphonium chloride. After sirring for 1 hour at room temperature a solution of 3.00g (0.017mol) 3,5- dichlorobenzaldehyde in 3 ml tetrahydrofuran were added and stirring was continued for 15 hours. Then 2 ml methanol were added, the solvents were evaporated and the residue chromatographed on silicagel with ethylacetate/hexane 2/8 to yield 1.17g (35%) (E)- and (Z)-3-(3,5-dichloro-phenyl)-acrylonitrile as white crystals. MS m/e (%): 197 (M + , 100). b) The title compound, mp. 257-260°C and MS m/e (%): 345 (M+H + , 100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5- furan-2-yl-lH-[l,2,4]triazole and 3-(3,5-dichloro-phenyl)-acrylonitrile Example 6 7- (4-Chloro-phenyl)-2-furan-2-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-ylamine 0.7g (0.015mol) sodiumhydride (55%) were added to a solution of 1.50g (0.005mol) 3- benzenesulfonylmethyl-5-furan-2-yl-lH-[ 1,2,4] triazole in 50 ml tetrahydrofuran. The mixture was refluxed and 0.85g (0.005mol) 3-(4-chlorophenyl)-2-propenenitrile in 30 ml tetrahydrofuran were added during aperiod of 5.5 hours. Boiling was continued for 30 minutes and then 20ml methanol were added at room temperature. Evaporation of the solvent and chromatography on silicagel with dichloromethane/methanol 99/1 gave 0.57g (35%) 7-(4-chloro-phenyl)-2-furan-2-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine as pale crystals. MS m/e (%): 311 (M+H + , 100). Example 7 2-Furan-2-yl-7-(2-methyl-pyridin-4-yl)- [ 1,2, 4] triazolo [ l,5-a]pyridin-5-ylamine The title compound, mp. 100-101°C and MS (El) m/e (%): 291 (M + , 100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-furan- 2-yl-lH-[ 1,2,4] triazole and (E)-3-(2-methyl-pyridin-4-yl)-acrylonitrile. Example 8 7- (2-Et_hyl-pyrio n-4-yl)-2-furan-2-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-ylamine a) (E)-3-(2-Ethyl-pyridin-4-yl)-acrylonitrile To a suspension of 1.79g (0.041mol) sodiumhydride in 50 ml tetrahydrofiirane and 50 ml dimethylformamide were added 13.9g (0.041mol) (cyanomethyl)triphenylphosphonium chloride. After sirring for 1 hour at room temperature a solution of 5.54g (0.041mol) 2- ethyl-4-pyridinecarboxaldehyde in 10 ml tetrahydrofuran were added and stirring was continued for 15 hours. Then 10 ml methanol were added, the solvents were evaporated and the residue chromatographed on aluminiumoxide with dichloromethane to yield 1.63g (25%) (E)-3-(2-ethyl-pyridin-4-yl)-acrylonitrile as white waxy solid. MS m/e (%): 158 (M + , 100). b) The title compound, mp. 184-186°C and MS m/e (%): 305 (M + , 100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-furan- 2-yl-lH-[l,2,4]triazole and (E)-3-(2-ethyl-pyridin-4-yl)-acrylonitrile. Example 9 2-Furan-2-yl-7- (2-propyl-pyridin-4-yl)- [ 1 ,2,4] triazolo [1,5-a] pyridin-5-ylamine a) 3-(2-Propyl-pyridin-4-yl)-acrylonitrile To a suspension of 1.39g (0.03mol) sodiumhydride in 40 ml tetrahydrofiirane and 40 ml dimethylformamide were added 10.13g (0.03mol) (cyanomethyl)triphenylphosphonium chloride. After sirring for 1 hour at room temperature a solution of 4.48g (0.03mol) 2- propyl-4-pyridinecarboxaldehyde in 15 ml tetrahydrofuran were added and stirring was continued for 15 hours. Then 10 ml methanol were added, the solvents were evaporated and the residue chromatographed on aluminiumoxide with dichloromethane to yield 2.42g 3-(2-propyl-pyridin-4-yl)-acrylonitrile as yellow oil. MS m/e (%): 173 (M+H + , 100). b) The title compound, MS m/e (%): 319 (M + , 100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-furan-2-yl-lH- [1,2,4] triazole and 3-(2-propyl-pyridin-4-yl)-acrylonitrile. Example 10 2-Furan-2-yl-7- (2-isopropyl-pyridin-4-yl)- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-ylamine a 3-(2-Isopropyl-pyridin-4-yl)-acrylonitrile To a suspension of 6.55g (0.15mol) sodiumhydride in 220 ml tetrahydrofiirane and 220 ml dimethylformamide were added 50.7g (0.15mol) (cyanomethyl)triphenylphosphonium chloride. After sirring for 1 hour at room temperature a solution of 22.4g (0.15mol) 2- isopropyl-4-pyridinecarboxaldehyde in 50 ml tetrahydrofuran were added and stirring was continued for 15 hours. Then 10 ml methanol were added, the solvents were evaporated and the residue chromatographed on aluminiumoxide with dichloromethane to yield 2.96g 3-(2-isopropyl-pyridin-4-yl)-acrylonitrile as coorless oil. MS m/e (%): 172 (M + , 100). b)The title compound, MS m/e (%): 320 (M+H + , 100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-furan-2-yl-lH- [1,2,4] triazole and 3-(2-isopropyl-pyridin-4-yl)-acrylonitrile. Example 11 7- (4-Fluoro-phenyl)-2-furan-2-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-ylarnine The title compound, MS m/e (%): 295 (M+H + , 100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-furan-2-yl-lH- [1,2,4] triazole and 3-(4-fluoro-phenyl)-acrylonitrile. Example 12 2-Furan-2-yl-7- ( 1 -oxy-pyridin-4-yl)- [ 1 ,2,4] triazolo [ 1 ,5-a] pyrid^n-5-ylarnine a) 3-( l-Oxy-pyridin-4-yl)-acrylonitrile A mixture of 10.4g (0.08mol) 3-(4-pyridinyl)-2-propenenitrile, O.lg (0.0006mol) methyltrioxorhenium, 15.5ml hydrogenperoxide and 300 ml dichloromethane were stirred at room temperature for 6 hours. Then a small quantity of manganese dioxide was added and stirring was continued for one hour. After extraction with dichloromethane/water the organic phase was dried with sodium sulfate and the solvent was distilled off. Chromatography on silicagel with dichloromethane/methanol 95/5 gave 3.3g (28%) 3-(l-oxy-pyridin-4-yl)-acrylonitrile (E:Z=1:1), MS m/e (%): 146 (M + , 100). b " ) 2-Furan-2-yl-7-(l-oxy-pyridin-4-yl)-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine The title compound, MS m/e (%): 294 (M+H + , 100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-furan-2-yl-lH- [1,2,4] triazole and 3-(l-oxy-pyτidin-4-yl)-acrylonitrile . Example 13 5-Arnino-2-furan-2-yl-7-pyridin-4-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridine-6-carbonitrile The title compound, MS m/e (%): 303 (M+H + , 100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-furan-2-yl-lH- [1,2,4] triazole and 4-pyτidinylmethylen-propanedinitril. Example 14 2-(5-Memyl-furan-2-yl)-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine a) 5-Methyl-furan-2-carboxylic acid (l-amino-2-benzenesulfonyl-ethylidene) -hydrazide A suspension of 85.0g (0.32mol) 2-(phenylsulfonyl)-ethanimidic acid ethyl ester hydrochloride in 700 ml chloroform was treated with 320 ml IN aqueous sodium hydroxide. 100 ml of a saturated aqueous sodiumbicarbonate solution was added and the mixture was extracted with chloroform. The extracts were combined and dried with sodium sulfate and the solvents were distilled off under reduced pressure. 17.8 g (0.078Mol) of the resulting colorless oil was stirred together with 9.15 g (0.065mol) 5- methyl-furan-2-carboxylic acid hydrazide in 115ml chloroform for 24 hours at 50°C. The resulting precipitate was filtered off and dried. 17.3g of 5-methyl-furan-2-carboxylic acid (l-amino-2-benzenesulfonyl-ethylidene)-hydrazide was obtained as white crystals. Mp.: 219-220°C. b) 3-Benzenesulfonylmethyl-5-methyl-furan-2-yl-lH-[ 1,2,4] triazole 8.0 g (0.025mol) 5-Methyl-furan-2-carboxylic acid (l-amino-2-benzenesulfonyl- ethylidene) -hydrazide were heated at 210oC for 20 minutes. The molten mass was then cooled, dissolved in 250 ml hot ethanol and stirred overnight at room temperature. The precipitated crystals were filtered off and subjected to column chromatography on silicagel with ethyl acetate hexanes 1:1 and 3:2 to yield 6.76 g (90%) 3-benzenesulfonylmethyl-5- methyl-furan-2-yl-lH-[ 1,2,4] triazole as white crystals.MS (El) m/e (%): 303 (M+H + , 16). c) 2-(5-Methyl-furan-2-yl)-7-pyridin-4-yl-[ l,2,4]triazolo[l,5-a1pyridin-5-ylamine The title compound was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-methyl-furan-2-yl-lH-[l,2,4]triazole and 3-(4- pyridinyl)-2-propenenitrile. Mp.: 270-272°C (dec). Example 15 N- [2- (5-Methyl-furan-2-yl)-7-pyridin-4-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-yl] -acetamide The title compound was obtained as a byproduct in the reaction above and isolated after chromatographic purification on SiO2 with 1% MeOH in dichloromethan. Mp.: 257- 259°C. Example 16 2- (4,5-Dimet yl-furan-2-yl)-7-pyridin-4-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyricun-5-ylarnine a) 4,5-Dimethyl-furan-2-carboxylic acid (l-amino-2-benzenesulfonyl-ethylidene - hvdrazide A suspension of l.lδg (0.004mol) 2-(phenylsulfonyl)-ethanimidic acid ethyl ester hydrochloride in 15 ml chloroform was treated with 6 ml IN aqueous sodium hydoxide. The mixture was extracted with dichloromethane. The extracts were combined and dried with magnesium sulfate and the solvents were distilled off under reduced pressure. The resulting colorless oil was stirred together with 0.68g (0.004mol) 4,5-dimethyl-furan-2- carboxylic acid hydrazide in 10ml chloroform for 24 hours at reflux temperature. Evaporation of the solvent and chromatography on silicagel with dichloromethane/methanol 19/1 gave 1.14g (76%) 4,5-dimethyl-furan-2-carboxylic acid (l-amino-2-benzenesulfonyl-ethylidene) -hydrazide as white crystals with mp. 197-199°C, MS m/e (%): 336 (M+H\ 100). b) 3-Benzenesulfonylmethyl-5-(4,5-dimethyl-furan-2-yl)-lH-[l,2,4ltriazole 0.92g (0.003mol) 4,5-Dimethyl-furan-2-carboxylic acid (l-amino-2-benzenesulfonyl- ethylidene)-hydrazide were heated at 200°C for 20 minutes. The molten mass was then cooled and purified by chromatography on silicagel with ethylacetate/hexane 7/3 to yield 0.76g (83%) 3-benzenesulfonylmethyl-5-(4,5-dimethyl-furan-2-yl)-lH-[l,2,4]triazole as white amorphous powder. MS m/e (%): 318 (M+H + , 100). c) 2-(4,5-Dimethyl-furan-2-yl)-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine , mp. 275-277°C, MS m/e (%): 306 (M+H + , 100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-(4,5-dimethyl-furan-2-yl)- lH-[l,2,4]triazole and 3-(4-pyridinyl)-2-propenenitrile. Example 17 2-Benzofuran-2-yl-7-pyridin-4-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-ylamine a) Benzofuran-2-carboxylic acid (l-amino-2-benzenesulfonyl-ethylidene)-hydrazide 3.4 g (0.0125 Mol) of 2-(phenylsulfonyl)-ethanimidic acid ethyl ester was stirred together with 2.2 g (0.015mol) benzo furan-2-carboxylic acid hydrazide in 80 ml chloroform for 24 hours at 50oC. The resulting precipitate was filtered off and dried. 2.67 g of benzofuran-2- carboxylic acid (l-amino-2-benzenesulfonyl-ethylidene)-hydrazide was obtained as off- white crystals. Mp.: 205-220°C. b) 3-Benzenesulfonylmethyl-benzofuran-2-yl-lH-[ 1,2,4] triazole 2.60 g (0.00727mol) Benzofuran-2-carboxylic acid (l-amino-2-benzenesulfonyl- ethylidene) -hydrazide were heated at 210oC for 20 minutes. The molten mass was then cooled, dissolved in 250 ml hot ethanol and stirred overnight at room temperature. The precipitated crystals were filtered off and subjected to column chromatography on SiO-2 with ethyl acetate hexanes 1:1 to yield 2.05 g (83%) 3-benzenesulfonylmethyl-benzofuran- 2-yl-lH-[l,2,4]triazole as white crystals, MS (El) m/e (%): 339 (M + , 24). c) 2-(Benzofuran-2-yl)-7-pyridin-4-yl-[l,2,4ltriazolo[l,5-a]pyridin-5-ylamine The title compound was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-benzofuran-2-yl-lH-[ 1,2,4] triazole and 3-(4-pyridinyl)-2- propenenitrile. Mp.: 270°C (dec). Example 18 7-Pyridin-4-yl-2-thiophen-2-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-ylamine a) Thiophene-2-carboxylic acid N'-(2-benzenesulfonyl-l-imino-ethyl)-hydrazide A suspension of 13.2g (0.05mol) 2-(phenylsulfonyl)-ethanimidic acid ethyl ester hydrochloride in 110 ml chloroform was treated with 50 ml IN aqueous sodium hydoxide. 20 ml of a saturated aqueous sodiumbicarbonate solution was added and the mixture was extracted with chloroform. The extracts were combined and dried with sodium sulfate and the solvents were distilled off under reduced pressure. The resulting colorless oil was stirred together with 7.82g (0.05mol) 2-thiophencarboxylic acid hydrazide in 75ml chloroform for 24 hours at 50°C. The resulting precipitate was filtered off and dried. A quantitative yield thiophene-2-carboxylic acid N'-(2-benzenesulfonyl-l-imino-ethyl)- hydrazide was obtained as white crystals. MS m/e (%): 324 (M+H + , 100). b) 3-BenzenesuIfonylmethyl-5-thiophen-2-yl-lH- 1,2,4] triazole l.OOg (0.003mol) Thiophene-2-carboxylic acid N'-(2-benzenesulfonyl-l-imino-ethyl)- hydrazide were heated at 200°C for 20 minutes. The molten mass was then cooled, dissolved in 5 ml hot ethanol and stirred for one hour at room temperature. The precipitated crystals were filtered off and dried to yield 0.87 g (93%) 3- benzenesulfonylmethyl-5-thiophen-2-yl-lH-[l,2,4]triazole as yellow crystals with mp. 191-193°C. MS m/e (%): 305 (M + , 100). c) 7-Pyτidin-4-yl-2-thiophen-2-yl-[ 1,2,4] triazolo [ 1,5-a] pyridin-5-ylamine, MS m/e (%): 293 (M + , 100), was prepared in accordance with the general method of example 1 from 3- benzenesulfonylmethyl-5-thiophen-2-yl- 1 H- [ 1 ,2,4] triazole and 3-pyridin-4-yl- acrylonitrile. Example 19 2- (5-Methyl-thiophen-2-yl)-7-pyτidin-4-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-ylamine a) 5-Methyl-thiophen-2-carboxylic acid (l-amino-2-benzenesulfonyI-ethylidene)- hydrazide 1.75 g (0.0077 Mol) of 2-(phenylsulfonyl)-ethanimidic acid ethyl ester was stirred together with 1.2 g (0.0077mol) 5-methyl-thiophen-2-carboxylic acid hydrazide in 14 ml chloroform for 24 hours at 50oC. The resulting precipitate was filtered off and dried. 2.37 g of 5-methyl-thiophen-2-carboxylic acid ( l-amino-2-benzenesulfonyl-ethylidene)- hydrazide was obtained as off-white crystals. Mp.: 222°C (dec). b) 3-Benzenesulfonylmethyl-5-methyl-thiophen-2-yl-lH- [ 1,2,4] triazole 2.33 g (0.0069mol) 5-Methylthiophen-2-carboxylic acid (l-amino-2-benzenesulfonyl- ethylidene) -hydrazide were heated at 210oC for 20 minutes. The molten mass was then cooled, dissolved in 250 ml hot ethanol and stirred overnight at room temperature. The precipitated crystals were filtered off and subjected to column chromatography on silicagel with ethyl acetate hexanes 2:1 to yield 2.05 g (92%) 3-benzenesulfonylmethyl-5-methyl- thiophen-2-yl-lH-[l,2,4]triazole as a yeUow foam, MS (El) m/e (%): 319 (M + , 24). c) 2-(5-Methyl-thiophen-2-yI)-7-pyridin-4-yl-[ 1,2,4] triazolo [ 1,5-a] pyridin-5-ylamine The title compound was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-methy-thiophen-2-yl-lH-[l,2,4]triazole and 3-(4- pyridinyl) -2-propenenitrile. Mp.: 254-256°C (dec). Example 20 N- [2- (5-Methyl-thiophen-2-yl)-7-pyridin-4-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-yl] - acetamide This compound was obtained as a byproduct in the reaction above as a yellow solid. Mp.: 226-228°C. Example 21 2-Pyridin-2-yl-7-pyridin-4-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-ylamine a) Pyridine-2-carboxylic acid (l-amino-2-benzenesulfonyl-ethylidene)-hydrazide A suspension of 9.24g (0.035mol) 2-(phenylsulfonyl)-ethanimidic acid ethyl ester hydrochloride in 100 ml chloroform was treated with 35 ml IN aqueous sodium hydoxide. 14 ml of a saturated aqueous sodiumbicarbonate solution was added and the mixture was extracted with chloroform. The extracts were combined and dried with sodium sulfate and the solvents were distilled off under reduced pressure. The resulting colorless oil was stirred together with 5.12g (0.037mol) 2-picolinyl hydrazide in 60 ml chloroform for 24 hours at 50°C. The resulting precipitate was filtered off and dried. A quantitative yield of pyridine-2-carboxylic acid (l-amino-2-benzenesulfonyl-ethylidene) -hydrazide was obtained as white crystals. MS m/e (%): 319 (M+H + , 100). b) 3-Benzenesulfonylmethyl-5-pyridin-2-yl-lH- l,2,4]triazole 7.70g (0.025mol) Pyridine-2-carboxylic acid (l-amino-2-benzenesulfonyl-ethylidene)- hydrazide were heated at 200°C for 20 minutes. The molten mass was then cooled, dissolved in 30 ml hot ethanol and stirred for two hous at room temperature. The precipitated crystals were filtered off and dried to yield 6.22 g (84%) 3- benzenesulfonylmethyl-5-pyridin-2-yl-lH- [ l,2,4]triazole. MS m/e (%): 300 (M + , 100). c) 2-Pyridin-2-yl-7-pyridin-4-yl-[ 1,2,4] triazolo [l,5-a1pyridin-5-ylamine The 2-pyridin-2-yl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, MS m/e (%): 289 (M+H + , 100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-pyridin-2-yl-lH-[l,2,4]triazole and 3-pyridin-4-yl- acrylonitrile. Example 22 2-Phenyl-7-pyridin-4-yl- [ 1 ,2,4] triazolo [ 1,5-a] pyridin-5-ylamine a) Benzenecarboxylic acid (l-amino-2-benzenesulfonyl-ethylidene)-hydrazide A suspension of 40.0g (0.15mol) 2-(phenylsulfonyl)-ethanimidic acid ethyl ester hydrochloride in 350 ml chloroform was treated with 150 ml IN aqueous sodium hydoxide. 60 ml of a saturated aqueous sodiumbicarbonate solution was added and the mixture was extracted with chloroform. The extracts were combined and dried with sodium sulfate and the solvents were distilled off under reduced pressure. The resulting colorless oil was stirred together with 22.4g (O.lόmol) benzhydrazide inl50 ml chloroform for 24 hours at 50°C. The solvent was distilled off and the residue was suspended in 150 ml ethanol and stirred for 5hours at room temperature. Filtration yielded 44.7g (93%) of benzenecarboxylic acid (l-amino-2-benzenesulfonyl-ethylidene)-hydrazide as white crystals with mp. 209-112°C. MS m/e (%): 318 (M+H + , 100). b) 3-Benzenesulfonylmethyl-5-phenyl- IH- [1,2,4] triazole 93. lg (0.29mol) Benzenecarboxylic acid (l-amino-2-benzenesulfonyl-ethylidene)- hydrazide were heated at 200°C for 30 minutes. The molten mass was then cooled, dissolved in 500 ml hot ethanol and stirred for 15 hous at room temperature. The precipitated crystals were filtered off and dried to yield 65.6 g (75%) 3- benzenesulfonylmethyl-5-phenyl-lH-[l,2,4]triazole with mp. 141-144°C. MS m/e (%): 299 (M\ 100). c) 2-Phenyl-7-pyridin-4-yl-[ 1,2,4] triazolo[l,5-a]pyridin-5-ylamine : To a boiling suspension of 78.8g(0.70mol) potassium tert-butoxide in 400 ml tetrahydrofuran was slowly added over a period of 5 hours a mixture of 70.1g (0.23mol) 3- benzenesulfonylmethyl-5-phenyl-lH-[ 1,2,4] triazole and 30.5g (0.23mol) 3-(4-pyridinyl)- 2-propenenitrile in 800 ml tetrahydrofuran. Boiling was continued for 18 hours and then the mixture was cooled to room temperature. Evaporation of the solvent and chromatography on silicagel with dichloromethane/methanol 95/5 gave 19.8g (29%) 2- phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine as yellow crystals with mp. 207-210°C, MS m/e (%): 287 (M + , 100). Example 23 2-Phenyl-7-pvridin-2-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-ylamine The title compound, mp. 278-280°C, MS m/e (%): 288 (M+H + , 100), was prepared in accordance with the general method of example 22 from 3-benzenesulfonylmethyl-5- phenyl-lH-[ 1,2,4] triazole and 3-pyridin-2-yl-acrylonitrile. Example 24 2-Phenyl-7-pyridin-3-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-ylamine The title compound, mp. 201-203°C, MS m/e (%): 288 (M+H\ 100), was prepared in accordance with the general method of example 22 from 3-benzenesulfonylmethyl-5- phenyl-lH-[ 1,2,4] triazole and 3-pyridin-3-yl-acrylonitrile. Example 25 2,7-Diphenyl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-ylamine The title compound, mp. 214-216°C, was prepared in accordance with the general method of example 22 from 3-benzenesulfonylmethyl-5-phenyl-lH-[l,2,4]triazole and cinnamonitrile. Example 26 5-Amino-2,7-diphenyl- [ 1 ,2,4] triazolo [1,5-a] pyridine-8-carbonitril A solution of 0.18g (O.OOlmol) 5-phenyl-lH-l,2,4-triazole-3-acetonitrile in 7 ml tetrahydrofuran was treated at -70°C with 1.56ml (0.0025mol) butyllithium (1.6 M in hexane). After one hour 0.21g (O.OOlmol) 3-bromo-3-phenyl-2-propenenitrile was added, stirring was continued for one hour, the mixture warmed to room temperature over night and water was added. Extraction with diethylether, chromatography on silicagel with dichloromethane/methanol 99/1 and crystallisation from diethylether gave 3.6 mg 5- amino-2,7-diphenyl-[l,2,4]triazolo[l,5-a]pyridine-8-carbonitril as white cystals. MS m/e (%): 312 (M+H + , 100). Example 27 But-3-enyl- (2-phenyl-7-pyridin-4-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-yl)-amine A solution of 0.20g (0.0007mol) 2-phenyl-7-pyridin-4-yl-[ 1,2,4] triazolo [1,5-a] pyridin-5- ylamine in 17.5 ml dimethylsulfoxide was treated with 0.69g (O.Olmol) potassiumhydroxide(85%) for 20 minutes at room temperature. Then 0.10g(0.0007mol) 4- bromo-1-butene were added and stirring was continued for 40 hours. Saturated aqueous sodiumbicarbonate was added and the mixture was extracted with ethylacetate. Evaporation of the solvent and chromatography on silicagel with dichloromethane/methanol 97/3 gave 0.04g(17%) but-3-enyl-(2-phenyl-7-pyridin-4-yl- [l,2,4]triazolo[l,5-a]pyridin-5-yl)-amine as beige crystals. MS m/e (%): 341 (M + , 21), 300 (100), 287 (65). Example 28 Ethyl-(2-phenyl-7-pyridin-4-yl- [ 1 ,2,4] triazolo [ 1 ,5-a]pvridin-5-yl)-amine A solution of 0.29g (O.OOlmol) 2-phenyl-7-pyridin-4-yl-[ 1,2,4] triazolo [1,5-a] pyridin-5- ylamine in 50ml dimethylformamide was treated with 0.05g (O.OOlmol) sodiumhydride(55%) for 15 minutes at room temperature. Then 0.22g (O.OOlmol) ethyl-p- toluenesulfonate were added and stirring was continued for 22 hours. Saturated aqueous sodiumbicarbonate was added and the mixture was extracted with dichloromethane. Evaporation of the solvent and chromatography on silicagel with dichloromethane/methanol 96/4 gave 0.37g(17%) ethyl-(2-phenyl-7-pyridin-4-yl- [l,2,4]triazolo[l,5-a]pyridin-5-yl)-amine as beige crystals. MS m/e (%): 316 (M+H + , 100). Example 29 (2-Phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin-5-yl)-carbamic acid ethyl ester The title compound, MS m/e (%): 360 (M+H + , 100), was prepared in accordance with the general method of example 27 from 2-phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin- 5-ylamine and ethyl chloroformate. Example 30 N- (2-Phenyl-7-pyridin-4-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-yl)-4-trifluoromethyl- benza ide A mixture of 0.29g (O.OOlmol) 2-phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin-5- ylamine and 1.13ml(0.014mol) pyridine in 30ml dichloromethane was stirred with 0.63g(0.003mol) p-trifluoromethyl benzoyl chloride for 18 hours at room temperature. Then another 0.63g(0.003mol) p-trifluoromethyl benzoyl chloride were added and stirring was continued at reflux temperaturefor 48 hours. After extraction with aqueous sodium hydroxide the organic solvents were distilled off and the residue was recrystallised from methanol to yield 0.28g(60%) N-(2-phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin-5- yl)-4-trifluoromethyl-benzamide as white crystals. MS m/e (%): 460 (M+H + , 100). Example 31 2- (2- Methoxy-phenyl)-N- (2-phenyl-7-pyridin-4-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-yl)- aceta ide A mixture of 0.29g (O.OOlmol) 2-phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin-5- ylamine and 1.13ml(0.014mol) pyridine in 30ml dichloromethane was stirred with 0.55g(0.003mol) 3-methoxyphenylacetyl chloride for 18 hours at room temperature. After extraction with aqueous sodium hydroxide the organic solvents were distilled off and the residue was purified by chromatography on silicagel with dichloromethane /methanol 98/2 and crystallisation from methanol to yield 0.25g(56%) 2-(2-methoxy-phenyl)-N-(2- phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin-5-yl)-acetamide as beige crystals. MS m/e (%): 436 (M+H + , 100). Example 32 2-(2-Chloro-phenyl)-N-(2-phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin-5-yl)- acetamide The title compound, MS m/e (%): 440 (M+H + , 100), was prepared in accordance with the general method of example 31 from 2-phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin- 5-ylamine and 2-chlorophenylacetyl chloride. Example 33 2- (2,4-Dichloro-phenyl)-N- (2-phenyl-7-pyridin-4-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-yl)- acetamide The title compound, MS m/e (%): 474 (M+H + , 100), was prepared in accordance with the general method of example 31 from 2-phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin- 5-ylamine and 2,4-dichlorophenylacetyl chloride. Example 34 2- (3-Chloro-phenyl)-N- (2-phenyl-7-pyridin-4-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-yl)- acetamide The title compound, MS m/e (%): 440 (M+H + , 100), was prepared in accordance with the general method of example 31 from 2-phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin- 5-ylamine and 3-chlorophenylacetyl chloride. Example 35 2- (3-Fluoro-phenyl)-N-(2-phenyl-7-pyridin-4-yl- [ 1 ,2,4] triazolo [ l,5-a]pyridin-5-yl)- acetamide The title compound, MS m/e (%): 424 (M+H + , 100), was prepared in accordance with the general method of example 31 from 2-phenyl-7-pyridin-4-yl-[ 1,2,4] triazolo [1,5-a] pyridin- 5-ylamine and 3-fluorophenylacetyl chloride. Example 36 N-(2-Phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin-5-yl)-2-(2-trifluoromethyl- phenyl)-acetamide The title compound, MS m/e (%): 474 (M+H + , 100), was prepared in accordance with the general method of example 31 from 2-phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin- 5-ylamine and 2-(trifluoromethyl)phenylacetyl chloride. Example 37 N-(2-Phenyl-7-pyri(lin-4-yl-[l,2,4]triazolo[l > 5-a]pyridin-5-yl)-2-(3-trifluoromethyl- phenyl)-acetamide The title compound, MS m/e (%): 474 (M+H + , 100), was prepared in accordance with the general method of example 31 from 2-phenyl-7-pyridin-4-yl-[ 1,2,4] triazolo [ 1,5-a] pyridin- 5-ylamine and 3-(trifluoromethyl)phenylacetyl chloride. Example 38 N- (2-Phenyl-7-pyridin-4-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-yl)-2- (4-trifluoromethyl- phenyl)-acetamide The title compound, MS m/e (%): 474 (M+H + , 100), was prepared in accordance with the general method of example 31 from 2-phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin- 5-ylamine and 4-(trifluoromethyl)phenylacetyl chloride. Example 39 3-Phenyl-N-(2-phenyl-7-pyrio n-4-yl-[l,2,4]txiazolo[l,5-a]pyrio n-5-yl)-propionamide The title compound, MS m/e (%): 420 (M+H + , 100), was prepared in accordance with the general method of example 31 from 2-phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin- 5 -ylamine and phenylpropionyl chloride. Example 40 (2-Phenyl-7-pyridin-4-yl-[ 1,2,4] triazolo [ 1,5-a] pyridin-5-yl)-carbamic acid phenyl ester The title compound, MS m/e (%): 408 (M+H + , 100), was prepared in accordance with the general method of example 31 from 2-phenyl-7-pyridin-4-yl-[ 1,2,4] triazolo [1,5-a] pyridin- 5-ylamine and phenyl chloroformate. Example 41 2-Phenyl-N- (2-phenyl-7-pyridin-4-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-yl)-acetamide The title compound, MS m/e (%): 406 (M+H + , 100), was prepared in accordance with the general method of example 31 from 2-phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin- 5-ylamine and phenylacetyl chloride. Example 42 N- (2-Phenyl-7-pyridin-4-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-yl)-benzamide The title compound, MS m/e (%): 391 (M + , 100), was prepared in accordance with the general method of example 31 from 2-phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin- 5-ylamine and benzoylchloride. Example 43 N- (2-Phenyl-7-pyridin-4-yl- [ 1 ,2,4] triazolo [1,5-a] pyridin-5-yl)-acetamide The title compound, MS m/e (%): 330 (M+H + , 100), was prepared in accordance with the general method of example 31 from 2-phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin- 5-ylamine and acetylchloride. Example 44 N- (2-Phenyl-7-pyridin-4-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-yl)-2-o-tolyl-acetamide The title compound, MS m/e (%): 420 (M+H + , 100), was prepared in accordance with the general method of example 31 from 2-phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin- 5-ylamine and o-tolylacetyl chloride. Example 45 2- (2-Bromo-phenyl)-N- (2-phenyl-7-pyridin-4-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-yl)- acetamide The title compound, MS m/e (%): 484,486 (M+H + , 100), was prepared in accordance with the general method of example 31 from 2-phenyl-7-pyridin-4-yl- [ 1 ,2,4] triazolo [1,5- a]pyridin-5-ylamine and o-bromphenylacetyl chloride. Example 46 2- (2-Iodo-phenyl)-N- (2-phenyl-7-pyridin-4-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-yl)- acetamide The title compound, MS m/e (%): 532 (M+H + , 100), was prepared in accordance with the general method of example 31 from 2-phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin- 5-ylamine and o-iodophenylacetyl chloride. Example 47 3-(2-Phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylcarbamoyl)-propyl]- carbamic acid tert-butyl ester A solution of 0.82g (0.004mol) Boc-4 aminobutyric acid and 0.66g (0.004mol) 1,1- carbonyl-diimidazole in 70 ml tetrahydrofuran was stirred at room temperature for one hour and was then added at room temperature to a suspension of 0.29g (O.OOlmol) 2- phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine and 0.10g (0.002mol) sodiumhydride(55%) in 50 ml dimethylformamide. After stirring at 80°C for 20 hours another 0.10 mg (0.002mol)sodiumhydride(55%) and 0.82g (0.004mol) Boc-4 aminobutyric acid were added and stirring was continued for 20 hours at 80°C. The solvent was evaporated, the residue taken up with saturated aqueous sodiumbicarbonate. Extraction with dichloromethane and chromatography on silicagel with dichloromethane/methanol gave 0.02g (5%) [3-(2-phenyl-7-pyridin-4-yl- [l,2,4]triazolo[l,5-a]pyridin-5-ylcarbamoyl)-propyl]-carbamic acid tert-butyl ester. MS m/e (%): 473 (M+H + , 100). Example 48 [2- (2-Methoxy-phenyl)-ethyl] - (2-phenyl-7-pyridin-4-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5- yl) -amine To 10 ml of a 1 molar solution of lithiumborohydride in tetrahydrofuran were added 2.17g (0.02mol) trimethylchlorosilane. After stirring for one hour at room temperature the suspension was added dropwise to a suspension of O.llg (0.25mol) 2-(2-methoxy-phenyl)- N-(2-phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin-5-yl)-acetamide and the mixture was heated for 18 hours at 50°C. Then 5 ml methanol were slowly added, the solvents were distilled off and the residue taken up in ethylacetate. The solution was washed with aqueous sodiumhydroxide and with water, dried with sodiumsulfate and evaporated. Recrystallisation from ethanol yielded 0.10g (94%) [2-(2-methoxy-phenyl)-ethyl]-(2- phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin-5-yl)-amine as beige crystals. MS m/e (%): 422 (M+H + , 100). Example 49 (2-Phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin-5-yl)-[2-(3-trifluoromethyl- phenyl)-ethyl] -amine The title compound, MS m/e (%): 460 (M+H + , 100), was prepared in accordance with the general method of example 48 from N-(2-Phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5- a]pyridin-5-yl)-2-(3-trifluoromethyl-phenyl)-acetamide. Example 50 2- (2-Chloro-phenyl)-ethyl] - (2-phenyl-7-pyridin-4-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-yl)- amine The title compound, MS m/e (%): 426 (M+H + , 100), was prepared in accordance with the general method of example 48 from 2-(2-Chloro-phenyl)-N-(2-phenyl-7-pyridin-4-yl- [ 1,2,4] triazolo[l,5-a]pyridin-5-yl)-acetamide. Example 51 2- (2,4-Dichloro-phenyl)-ethyl] - (2-phenyl-7-pyridin-4-yl- [ 1 ,2,4] triazolo [1,5-a] pyridin-5- yl)-amine The title compound, MS m/e (%): 460 (M+H + , 100), was prepared in accordance with the general method of example 48 from 2-(2,4-dichloro-phenyl)-N-(2-phenyl-7-pyridin-4-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-yl)-acetamide. Example 52 2- (3-Chloro-phenyl)-ethyl] - (2-phenyl-7-pyridin-4-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-yl)- amine The title compound, MS m/e (%): 426 (M+H + , 100), was prepared in accordance with the general method of example 48 from 2-(3-chloro-phenyl)-N-(2-phenyl-7-pyridin-4-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-yl)-acetamide. Example 53 (2-Phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin-5-yl)-(4-trifluoromethyl-benzyl)- amine The title compound, MS m/e (%): 446(M+H + , 100), was prepared in accordance with the general method of example 48 from N-(2-phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5- a]pyridin-5-yl)-4-trifluoromethyl-benzamide. Example 54 2-(3-Fluoro-phenyl)-ethyl]-(2-phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin-5-yl)- amine The title compound, MS m/e (%): 410 (M+H + , 100), was prepared in accordance with the general method of example 48 from 2-(3-fluoro-phenyl)-N-(2-phenyl-7-pyridin-4-yl- [l,2,4]triazolo[l,5-a]pyridin-5-yl)-acetamide. Example 55 (2-Phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin-5-yl)-[2-(2-trifluoromethyl- phenyl)-ethyl] -amine The title compound, MS m/e (%): 460(M+H + , 100), was prepared in accordance with the general method of example 48 from N-(2-phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5- a]pyridin-5-yl)-2-(2-trifluoromethyl-phenyl)-acetamide. Example 56 (2-Phenyl-7-pyri(lin-4-yl-[l,2,4]triazolo[l,5-a]pyridin-5-yl)-[2-(4-trifluoromethyl- phenyl)-ethyl] -amine The title compound, MS m/e (%): 460 (M+H + , 100), was prepared in accordance with the general method of example 48 from N-(2-phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5- a]pyridin-5-yl)-2-(4-trifluoromethyl-phenyl)-acetamide. Example 57 (3-Phenyl-propyl)- (2-phenyl-7-pyridin-4-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-yl)-amine The title compound, MS m/e (%): 406 (M+H + , 100), was prepared in accordance with the general method of example 48 from 3-phenyl-N-(2-phenyl-7-pyridin-4-yl- [ 1,2, 4] triazolo [ l,5-a]pyridin-5-yl)-propionamide. Example 58 Dibenzyl-(2-phenyl-7-pyridin-4-yl- [ 1,2,4] triazolo [ l,5-a]pyridin-5-yl)-amine A solution of 0.20g (0.0007mol) 2-phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin-5- ylamine in 17.5 ml dimethylsulfoxide was treated with 0.69g (O.Olmol) potassiumhydroxide(85%) for 20 minutes at room temperature. Then 0.26g (0.0015mol) benzylbromide were added and stirring was continued for 70 hours. Saturated aqueous sodiumbicarbonate was added and the mixture was extracted with chloroform. Evaporation of the solvent and chromatography on silicagel with dichloromethane/methanol 98/2 and crystallisation from diethylether gave 0.12g (44%) dibenzyl-(2-phenyl-7-pyridin-4-yl- [ 1,2,4] triazolo [ 1,5-a] pyridin-5-yl)-amine as light brown crystals. MS m/e (%): 468 (M+H + , 100). Example 59 Diethyl- (2-phenyl-7-pyridin-4-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-yl)-arnine A solution of 0.29g (O.OOlmol) 2-phenyl-7-pyτidin-4-yl-[ 1,2,4] triazolo [1,5-a] pyridin-5- ylamine in 50ml dimethylformamide was treated with 0.05g (O.OOlmol) sodiumhydride(55%) for 15 minutes at room temperature. Then 0.22g (O.OOlmol) ethyl-p- toluenesulfonate were added and stirring was continued for 22 hours. Addition of sodiumhydride and p-toluenesulfonate was repeated three times. After each addition stirring was continued at 50°C for 20 hours. Saturated aqueous sodiumbicarbonate was added and the mixture was extracted with dichloromethane. Evaporation of the solvent and chromatography on silicagel with dichloromethane/methanol 96/4 gave 0.05g (15%) diethyl-(2-phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin-5-yl)-amine as yellow oil. MS m/e (%): 343 (M + , 59), 314 (100), 300 (73), 104 (51). Example 60 2- [ 1 - (2-Phenyl-7-pvridin-4-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-yl)-4,5 dihydro- 1 H- imidazol-2-yl]-benzoic acid The title compound, MS m/e (%): 461 (M+H + , 100), was prepared in accordance with the general method of example 27 from 2-phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin- 5-ylamine and N-(2-bromoethyl)-phthalimide. Example 61 2- [ 1- (2-Phenyl-7-pyridin-4-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-yl)- 1 ,4,5,6-tetrahydro- pyrimidin-2-yl]-benzoic acid The title compound, MS m/e (%): 475 (M+H + , 100), was prepared in accordance with the general method of example 27 from 2-phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin- 5-ylamine and N-(3-bromopropyl)-phthalimide. Example 62 2- [ 1 - (2-Phenyl-7-pyridin-4-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-yl)-4,5,6,7-tetrahydro- 1 H- [l,3]diazepin-2-yl]-benzoic acid The title compound, MS m/e (%): 489 (M+H + , 100), was prepared in accordance with the general method of example 27 from 2-phenyl-7-pyridin-4-yl-[ 1,2,4] triazolo [1,5-a] pyridin- 5-ylamine and N-(4-bromobutyl)-phthalimide. Example 63 2-Phenyl-7-p-tolyl-3H- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-ylamine a) 4-Bromo-pyridine-2,6-dicarboxylic acid diethyl ester A mixture of 4.02g (20mmol) chelidamic acid monohydrate and 34.4g (80mmol) PBr 5 in 60 ml CC1 4 was heated to reflux for 12h and afterwards cautiously treated with 20 ml EtOH. After 30min at 80°C the mixture was cooled to room temperature and the volatile components distilled off under reduced pressure. The remaining residue was treated with 200ml ice/water mixture and stirred for lh. The white precipitate was filtered off washed with water and dried in high vacuum to yield 5.61g (92.9%) of 4-bromo-pyridine-2,6- dicarboxylic acid diethyl ester, MS m/e (%): 302 (M+H + , 4), 229 (M + -(CO 2 Et), 100) b) 4-Bromo-pyridine-2,6-dicarboxylic acid dihydrazide A solution of 4.76g (15.7mmol) 4-bromo-pyridine-2,6-dicarboxylic acid diethyl ester in 87ml ethanol was treated with 18.3 ml of a 24% solution of hydrazine in water and heated to 80°C. The formed white suspension was filtered hot and the collected white precipitate was dried to yield 3.51g (81.4%) of the title compound, MS m/e (%): 276 (M + +2, 100). c) 4-Bromo-pyridine-2,6-diamine A suspension of lg (3.65mmol) 4-bromo-pyridine-2,6-dicarboxylic acid dihydrazide in 32ml water was treated with 1.6ml HCl (37%) at room temperature. The resulting mixture was cooled to 0°C and 554mg NaNO 2 in 2.4ml water was added slowly maintainig the temperature below 2°C. Upon completion saturated NaHCO 3 solution was added to pH ~8 and the white precipitate was filtered off and washed with water. The residue was dissolved in CHC1 3 and dried with MgSO 4 . The filtrate was concentrated at 20°C to yield 920mg (85%) of a white solid 450mg (1.5mmol) of the white residue were suspended in toluene/t-butanol 5/1. After refluxing for 12h the solvent was removed under reduced pressure and 5ml toluene and 0.3ml trifluoroacetic acid were added and refluxed for 2h. The solvents were removed and the residue was purified by flash chromatography on silica eluting with dichloromethane/methanol 9/1. After removal of the solvents the title compound was liberated through addition of IN NaOH to a suspension of the residue in diethylether. The organic phase was dried with Na 2 SO 4 and the solvents removed under reduced pressure yielding 192mg (67%) of the desired product, MS m/e (%): 188 (M + , 100). d)7-Bromo-2-phenyl- [1,2,4] triazolo [l,5-alpyridin-5-ylamine To a solution of 96mg (0.51 mmol) 4-bromo-pyridine-2,6-diamine in 2.4ml MeOH was added 121mg (0.56mmol) O-mesitylenesulfonylhydroxylamine (prepared from ethyl o- mesitylenesulfonylacetohydroxamate and HClO (70%)) in 0.6ml MeOH at -5°C and after 15min 71mg (0.56mmol) benzaldehyde and stirred for 30min. The addition of 4.8ml IN KOH was followed by extraction with ethylacetate, drying of the organic layer with Na 2 SO , and removal of the volatile components. The residue was purified by column chromatography on silica eluting with ethylacetate and hexane (2:3). 58 mg(39%) of 7- bromo-2-phenyl-[ 1,2,4] triazolo [ 1,5-a] pyridin-5-ylamine were isolated, MS m/e (%): 290 (M + +2, 44). e) 2-Phenyl-7-p-tolyl-3H- [1,2,4] triazolo [ 1 ,5-a] pyridin-5-ylamine A mixture of 30mg (O.lmmol) 7-bromo-2-phenyl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 15.5mg (O.l lmmol) p-tolyl-boronic acid, and 0.1ml aqueous 2M Na 2 CO 3 in 0.5ml 1,2- dimethoxyethane was treated with 6mg (O.Olmmol) tetrakis-(triphenylphosphine)- palladium(O) and heated to 90°C for 15h. Water was added and the mixture was adjusted to pH=12 with 2M NaOH and extracted with ethylacetate. The organic phases were dried with Na 2 SO 4 and concentrated under reduced pressure yielding 22mg (71%) 2-phenyl-7-p- tolyl-3H-[ 1,2,4] triazolo [ 1,5-a] pyridin-5-ylamine, MS m/e (%): 300 (M + , 100). Example 64 7-Bromo-2-furan-2-yl- [ 1 ,2,4] triazolo [1,5-a] pyridin-5-ylamine The title compound, MS m/e (%): 281 (M + +2, 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene- sulfonylhydroxylamine, and furfural. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient. Example 65 7-Bromo-2- (5-methyl-furan-2-yl)- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin- 5-ylamine The title compound, MS m/e (%): 295 (M + +2, 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene- sulfonylhydroxylamine, and 5-methyl- furfural. The purification was performed with reversed phase HPLC eluting a with an acetonitrile/water gradient. Example 66 [5- (5-Amino-7-bromo- [ 1 ,2,4] triazolo [ 1 ,5-a] pyτidin-2-yl)-furan-2-yl] -methanol The title compound, MS m/e (%): 311 (M + +2, 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene- sulfonylhydroxylamine, and 5-hydroxymethyl-furfural. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient. Example 67 7-Bromo-2-(5-bromo-furan-2-yl)-[l,2,4]triazolo[l,5-a]pyridin- 5-ylamine The title compound, MS m/e (%): 359 (M + +l, 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyτidine-2,6-diamine, O-mesitylene- sulfonylhydroxylamine, and 5-bromo-furfural. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient. Example 68 7-Bromo-2- (4-bromo-furan-2-yl)- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-ylamine The title compound, MS m/e (%): 359 (M + +l, 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene- sulfonylhydroxylamine, and 4-bromo- urfural. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient. Example 69 7-Bromo-2-(2-furan-2-yl-vmyl)-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine The title compound, MS m/e (%): 305 (M + , 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene- sulfonylhydroxylamine, and 3-(2-furyl)-acrolein. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient. Example 70 7-Bromo-2-thiophen-2-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine The title compound, MS m/e (%): 297 (M + +2, 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene- sulfonylhydroxylamine, and 2-thiophenecarboxaldehyde. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient. Example 71 7-Bromo-2- (3-methyl-thiophen-2-yl)- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin- 5-ylamine The title compound, MS m/e (%): 309 (M + , 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene- sulfonylhydroxylamine, and 3-methylthiophene-2-carboxaldehyde. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient. Example 72 7-Bromo-2- (4-bromo-thiophen-2-yl)- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-ylamine The title compound, MS m/e (%): 375 (M + +l, 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene- sulfonylhydroxylamine, and 4-bromothiophene-2-carboxaldehyde. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient. Example 73 7-Bromo-2-(l -methyl- lH-pyrrol-2-yl)- [1,2,4] triazolo [ 1,5-a] pyridin-5-ylarnine The title compound, MS m/e (%): 294 (M + +2, 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene- sulfonylhydroxylamine, and l-methylpyrrole-2-carboxaldehyde. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient. Example 74 7-Bromo-2-thiazol-2-yl-[ 1,2,4] triazolo [ 1,5-a] pyridin-5-ylamine The title compound, MS m/e (%): 298 (M + +2, 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene- sulfonylhydroxylamine, and 2-formylfhiazole. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient. Example 75 7-Bromo-2-pyridin-4-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-ylamine The title compound, MS m/e (%): 292 (M + +2, 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene- sulfonylhydroxylamine, and 4-pyridinecarboxaldehyde. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient. Example 76 7-Bromo-2- (6-methyl-pyridin-2-yl)- [ 1 ,2,4] triazolo [1,5-a] pyridin- 5-ylamine The title compound, MS m/e (%): 306 (M + +2, 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene- sulfonylhydroxylamine, and 6-methylpyridine-2-aldehyde. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient. Example 77 7- Bromo-2- ( 1 H-indol-3-yl)- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin- 5-ylamine The title compound, MS m/e (%): 328 (M + , 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene- sulfonylhydroxylamine, and indole-3-carboxaldehyde. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient. Example 78 2- (5- Amino- 7-bromo- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-2-yl)-phenol The title compound, MS m/e (%): 307 (M + +2, 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene- sulfonylhydroxylamine, and salicylaldehyde. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient. Example 79 7-Bromo-2- (2-methoxy-phenyl)- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin- 5-ylamine The title compound, MS m/e (%): 321 (M + +2, 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene- sulfonylhydroxylamine, and o-anisaldehyde. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient. Example 80 7-Bromo-2- (5-ethyl-furan-2-yl)- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-ylamine The title compound, MS m/e (%): 309 (M + +2, 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene- sulfonylhydroxylamine, and 5-ethyl-2-furaldehyde. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient. Example 81 7-Bromo-2-furan-3-yl- [ 1,2,4] triazolo [ l,5-a]pyridin-5-ylamine The title compound, MS m/e (%): 281 (M + +2, 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene- sulfonylhydroxylamine, and 3-furaldehyde. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient. Example 82 7-Bromo-2-(5-methyl-thiophen-2-yl)-[l,2,4]triazolo[l,5-a]pyridin- 5-ylamine The title compound, MS m/e (%): 311 (M + +2, 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene- sulfonylhydroxylamine, and 5-methyl-2-thiophenecarboxaldehyde. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient. Example 83 7-Bromo-2-(tetrahydro-furan-2-yl)- [ 1,2,4] triazolo [ 1,5-a] pyridin-5-ylamine The title compound, MS m/e (%): 283 (M + , 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene- sulfonylhydroxylamine, and tetrahydro-furan-2-carbaldehyde. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient. Example 84 7-Bromo-2- (3-fluoro-phenyl)- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-ylamine The title compound, MS m/e (%): 307 (M + , 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene- sulfonylhydroxylamine, and 3-fluoro-benzaldehyde. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient. Example 85 7-Bromo-2- (5-methoxy-thiophen-2-yl)- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin- 5-ylarnine The title compound, MS m/e (%): 325 (M + , 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyτidine-2,6-diamine, O-mesitylene- sulfonylhydroxylamine, and 5-methoxy-thiophene-2-carbaldehyde. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient. Example 86 7-Bromo-2-(4-methoxy-thiophen-2-yl)- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin- 5-ylamine The title compound, MS m/e (%): 325 (M + , 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene- sulfonylhydroxylamine, and 4-methoxy-thiophene-2-carbaldehyde. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient. Example 87 7-Bromo-2-(5,6-dihydro-4H-pyran-2-yl)-[l,2,4]triazolo[l,5-a]pyri(lin-5-ylamine The title compound, MS m/e (%): 295 (M + , 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene- sulfonylhydroxylamine, and 5,6-dihydro-4H-pyran-2-carbaldehyde. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient. Example 88 7-Bromo-2-pyridin-2-yl- [ 1 ,2,4] triazolo [ 1,5-a] pyridin-5-ylamine The title compound, MS m/e (%): 290 (M + , 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene- sulfonylhydroxylamine, and pyridine-2-carbaldehyde. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient. Example 89 7-Bromo-2-(2-fluoro-phenyl)-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine The title compound, MS m/e (%): 290 (M + , 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene- sulfonylhydroxylamine, and 2-fluoro-benzaldehyde. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient. Example 90 7-Bromo-2-(6-methoxy-pyridin-2-yl)-[l,2,4]triazolo[l,5-a]pyri<im-5-ylarnine The tide compound, MS m/e (%): 320 (M + , 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene- sulfonylhydroxylamine, and 6-methoxy-pyridine-2-carbaldehyde. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient. Example 91 7-Bromo-2-isoxazol-5-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridm-5-ylamine The title compound, MS m/e (%): 280 (M + , 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene- sulfonylhydroxylamine, and isoxazole-5-carbaldehyde. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient. Example 92 7- (4-Methoxy-phenyl)-2-pyridin-2-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-ylamine A mixture of 72.5 mg (0.25mmol) 7-bromo-2-pyridin-2-yl-[l,2,4]triazolo[l,5-a]pyridin-5- ylamine, 37.4 mg (0.275mmol) p-methoxy-boronic acid, and 0.22 ml 2M Na 2 CO 3 in 0.78 ml dioxane was treated with 0.05 eq. dichloro (l,l'-bis(diphenylphosphino) ferrocene)palladium (II) dichloromethane adduct and heated to 100°C for 15 h. Formic acid was added and the mixture was purified by reversed phase column chromatography eluting with an acetonitrile/water gradient yielding 13.3 mg (17%) of the title compound. MS m/e (%): 318 (M+H\ 100) According to example 63 or example 92 triazolopyridine derivatives have been synthesised. The results are compiled in the following list comprising example 93 to example 220 MS Example Structure name MW Syntesis according No. m/e (%) to example No. 126 2-Furan-2-yl-7-(3- M+H + (100) 306.3 63 methoxy-phenyl ) - [1,2,4] triazolo [ 1,5- a]pyridin-5-ylamine 127 N-[3-(5-Amino-2-furan- M+H + (100) 333.4 63 2-yl-[l,2,4]triazolo[l,5- a]pyridin-7-yl)-phenyl] - acetamide 128 2-Furan-2-yl-7-(4- M+H + (100) 360.3 63 trifluoromethoxy- phenyl)- l,2,4]triazolo[ l,5- a] pyridin-5-ylamine 129 7-Benzo[l,3]dioxol-5-yl- M+H + (100) 320.3 63 2-furan-2-yl- 1, 2,4] triazolo[ 1,5- a]pyridin-5-ylamine 130 2-Furan-2-yl-7-(lH- M+H + (100) 315.3 63 indol-5-yl)- l,2,4]triazolo[l,5- a]pyridin-5-ylamine 131 3-(5-Amino-2-furan-2- M+H + (100) 301.3 63 yl- [1,2,4] triazolo [1,5- a]pyridin-7-yl)- benzonitrile MS Syntesis Example Structure name MW according No. m/e (%) to example No. 165 7-(2-FIuoro-phenyl)-2- M+H + (100) 305.3 92 pyridin-2-yl- [l,2,4]triazolo[ l,5- a]pyridin-5-ylamine 166 7-(3-Fluoro-phenyl)-2- M+H + (100) 305.3 92 pyridin-2-yl- [l,2,4]triazolo[ l,5- a]pyridin-5-ylamine 167 7-(4-Fluoro-phenyl)-2- M+H + (100) 305.3 92 pyridin-2-yl- [l,2,4]triazolo[l,5- a]pyridin-5-ylamine 168 7-(3-Chloro-4-fluoro- M + (100) 339.8 92 phenyl)-2-pyridin-2-yl- l,2,4]triazolo[ l,5- a] pyridin-5 -ylamine 169 7-(2-Chloro-ρhenyl)-2- M + (100) 321.8 92 pyridin-2-yl- l,2,4]triazolo[l,5- a]pyridin-5-ylamine 170 7-(3-Chloro-phenyl)-2- M + (100) 321.8 92 pyridin-2-yl- l,2,4]triazolo[l,5- a] pyridin-5 -ylamine 171 7-(4-Chloro-phenyl)-2- M + (100) 321.8 92 pyridin-2-yl- 1,2,4] triazolo [1,5- a]pyridin-5-ylamine MS , .... Syntesis Example Structure name MW ' ,. according No. m/e (%) to example No. 179 N-[3-(5-Amino-2- M+H + (100) 344.4 92 pyridin-2-yl- [ 1,2,4] triazolo [ 1,5- a]pyridin-7-yl)-phenyl] - acetamide 180 N-[4-(5-Amino-2- M+H + (100) 344.4 92 pyridin-2-yl- l,2,4]triazolo[ l,5- a]pyridin-7-yl)-phenyl] - acetamide 181 7-(3-Amino-phenyl)-2- M+H + (100) 302.3 92 pyridin-2-yl- l,2,4]triazolo[l,5- a ] pyridin - 5 -ylamine 182 2-Isoxazol-5-yl-7- M+H + (100) 277.3 92 phenyl- l,2,4]triazolo[l,5- a] pyridin-5-ylamine 183 7-(2-Fluoro-phenyl)-2- M+H + (100) 295.3 92 isoxazol-5-yl- l,2,4]triazolo[ l,5- a] pyridin-5-ylamine 184 7-(3-Fluoro-phenyl)-2- M+H + (100) 295.3 92 isoxazol-5-yl- [ 1,2,4] triazolo [1,5- a] pyridin-5-ylamine MS e Syntesis Example Structur name MW according No. m/e (%) to example No. 185 7-(4-Fluoro-phenyl) -2 - M+H + (100) 295.3 92 isoxazol-5-yl- l,2,4]triazolo[ l,5- a]pyridin-5-ylamine 186 7-(3-Chloro-4-fluoro- M + (100) 329.7 92 phenyl)-2-isoxazol-5-yl- [ 1,2,4] triazolo [1,5- a] pyridin-5-ylamine 187 7-(3-Chloro-phenyl)-2- M + (100) 311.7 92 isoxazol-5-yl- [ l,2,4]triazolo[l,5- a] pyridin - 5 -ylamine 188 7- (3,4-Dichloro-phenyl) - M + (100) 346.2 92 2-isoxazol-5-yl- l,2,4]triazolo[ l,5- a ] pyridin - 5 -ylamine 189 2-Isoxazol-5-yl-7-(3- M+H + (100) 307.3 92 methoxy-phenyl) - l,2,4]triazolo[ l,5- a] pyridin -5 -ylamine 190 2-Isoxazol-5-yl-7-(4- M+H + (100) 307.3 92 methoxy-phenyl ) - 1, 2,4] triazolo [ 1,5- a] pyridin-5-ylamine 191 7- ( 3 ,4-Dimethoxy- M+H + (100) 337.3 92 phenyl)-2-isoxazol-5-yl- l,2,4]triazolo[l,5- a] pyridin-5-ylamine MS Syntesis Example Structure name MW according No. m/e (%) to example No. 199 2-(4,5-Dihydro-furan-2- M+H + (100) 296.3 92 yl)-7-(4-fluoro-phenyl)- [ 1,2,4] triazolo [ 1,5- a]pyridin-5-ylamine 200 2-(4,5-Dihydro-furan-2- M+H + (100) 292.3 92 yl)-7-m-tolyl- l,2,4]triazolo[l,5- a] pyridin-5 -ylamine 201 2-(4,5-Dihydro-furan-2- M+H + (100) 346.3 92 yl)-7-(3-trifluoromethyl- phenyl)- l,2,4]triazolo[l,5- a]pyridin-5-ylamine 202 N-{4-[5-Amino-2-(4,5- M+H + (100) 335.4 92 dihydro-furan-2-yl)- l,2,4]triazolo[ l,5- a]pyridin-7-yl] -phenyl}- acetamide 203 2-(6-Methoxy-pyridin-2- M+H + (100) 317.4 92 yl)-7-phenyl- 1, 2,4] triazolo [ 1,5- a]pyridin-5-ylamine 204 2 - ( 5-Methoxy-thiophen - M+H + (100) 322.4 92 2-yl)-7-phenyl- l,2,4]triazolo[ l,5- a] pyridin-5-ylamine Example 221 7-Morpholin-4-yl-2-phenyl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-ylamine (RO-69-0728/000) A mixture of 40mg (0.138 mmol) 7-bromo-2-phenyl-[l,2,4]triazolo[l,5-a]pyridin-5- ylamine, 241 ul (2.8mmol) morpholin and 225mg (0.69mmol) Cs 2 CO 3 in 200ul DMF was heated 20h to 140°C. Filtration and subsequent purification with reversed phase column chromatography eluting with an acetonitrile/water gradient yielded 20mg (49%) of the title compound, MS m/e (%): 296 M+H + (100%). According to example 221 triazolopyridine derivatives have been synthesised through the reaction of the appropiate bromide substituted triazolo-pyridine with the respective amine and subsequently isolated with reversed phase column chromatography eluting with an acetonitrile/water gradient. The results are compiled in the following list comprising example 222 to example 255. For some examples N-mefhyl-pyrolidon (NMP) at 160°C was used instead of DMF at 140°. This is indicated in the following list with the additional comment "NMP" respectively "DMF". Example 256 2-Furan-2-yl-7- (4-mefhoxy-phenoxy)- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-ylamine A mixture of leq. 7-bromo-2-furan-2-yl-[ 1,2,4] triazolo [l,5-a]pyridin-5-ylamine, 5eq. p- methoxy-phenol and a catalytic amount of Cs 2 CO 3 in 200μl N-methyl-pyrrolidon was heated for 2h to 160°. The mixture was, after filtration, purified with reversed phase column chromatography eluting with an acetonitrile/water gradient yielding the title compound, MS m/e (%): 322 M+H + (100%). Example 257 7- (4-Bromo-phenoxy)-2-furan-2-yl- [ 1 ,2,4] triazolo [1,5-a] yridin-5-ylamine A mixture of leq. 7-bromo-2-furan-2-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 5eq. p- bromo-phenol and a catalytic amount of Cs 2 CO 3 in 200μl N-methyl-pyrrolidon was heated for 2h to 160°. The mixture was, after filtration, purified with reversed phase column chromatography eluting with an acetonitrile/water gradient yielding the title compound, MS m/e (%): 37l M + (100%). Example 258 2-Furan-2-yl-7- (5,6,7,8- tetrahydro-naphthalen- 1 -yloxy)- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5- ylamine A mixture of leq. 7-bromo-2-furan-2-yl-[ 1,2,4] triazolo [ 1,5-a] pyridin-5-ylamine, 5eq. 5,6,7,8-tetrahydro-naphthalen-l-ol and a catalytic amount of Cs 2 CO 3 in 200ul N-methyl- pyrrolidon was heated for 2h to 160°. The mixture was, after filtration, purified with reversed phase column chromatography eluting with an acetonitrile/water gradient yielding the title compound, MS m/e (%): 346 M+H + (100%). Example 259 2-Furan-2-yl-7-p-tolyloxy- [1,2,4] triazolo [ 1,5-a] pyridin-5-ylamine (RO-69-2954/000) A mixture of leq. 7-bromo-2-furan-2-yl-[ 1,2,4] triazolo [ 1,5-a] pyridin-5-ylamine, 5eq. p- methyl-phenol and a catalytic amount of Cs 2 CO 3 in 200μl N-methyl-pyrrolidon was heated for 2h to 160°. The mixture was, after filtration, purified with reversed phase column chromatography eluting with an acetonitrile/water gradient yielding the title compound, MS m/e (%): 306 M+H + ( 100%). Example 260 7- (3-Fluoro-phenoxy)-2-furan-2-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin- 5-ylamine A mixture of leq. 7-bromo-2-furan-2-yl-[ l,2,4]triazolo[ l,5-a]pyridin-5-ylamine, 5eq. m- fluoro-phenol and a catalytic amount of Cs 2 CO 3 in 200μl N-methyl-pyrrolidon was heated for 2h to 160°. The mixture was, after filtration, purified with reversed phase column chromatography eluting with an acetonitrile/water gradient yielding the title compound, MS m/e (%): 310 M+H + (100%). Example 261 2-Furan-2-yl- 7- (5,6,7,8-tetrahydro-naphthalen-2-yloxy)- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5- ylamine A mixture of leq. 7-bromo-2-furan-2-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 5eq. 5,6,7,8-tetrahydro-naphthalen-2-ol and a catalytic amount of Cs 2 CO 3 in 200μl N-methyl- pyrrolidon was heated for 2h to 160°. The mixture was, after filtration, purified with reversed phase column chromatography eluting with an acetonitrile/water gradient yielding the title compound, MS m/e (%): 346 M+H + (100%). Example 262 7-(6-Methyl-pyridin-2-ylmethoxy)-2-pyridin-2-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin- 5-ylamine A mixture of leq. 7-bromo-2-pyτidin-2-yl- [1,2,4] triazolo [ 1,5-a] pyridin-5-ylamine, 5eq. (6-rnethyl-pyridin-2-yl)-mefhanol and a catalytic amount of Cs 2 CO 3 in 200μl N-methyl- pyrrolidon was heated for 2h to 160°. The mixture was, after filtration, purified with reversed phase column chromatography eluting with an acetonitrile/water gradient yielding the title compound, MS m/e (%): 332 M+H + (100%). Example 263 7-Phenoxy-2-pyridin-2-yl- [ 1 ,2,4] triazolo [1,5-a] pyridin-5-ylamine A mixture of leq. 7-bromo-2-pyridin-2-yl-[l,2,4]triazolo[ l,5-a]pyridin-5-ylamine, 5eq. phenol and a catalytic amount of Cs 2 CO 3 in 200μl N-methyl-pyrrolidon was heated for 2h to 160°. The mixture was, after filtration, purified with reversed phase column chromatography eluting with an acetonitrile/water gradient yielding the title compound, MS m/e (%): 303 M+H + (100%). Example 264 4-(3,4-Dichloro-phenyl)-pyridine-2,6-diamine A mixture of 40.5mg (0.21 mmol) 2,6-diamino-4-bromo-pyridine, 90.5mg (0.47mmol) 3,4-dichloro-phenyl-boronic acid, 7.8mg (O.Olmmol) Dichloro(l,l'- bis(diphenylphosphino) ferrocene)palladium (II) dichloromethane adduct and 0.3ml 2M Na 2 CO 3 in 1 ml dimethoxyethane was heated to 80°C for 17 h. The mixture was filtered over silica washed with MeOH/DCM and concentrated. The residue was taken up in 1ml DMF and the totle compound was purified by reversed phase column chromatography eluting wit an acetonitrile/water gradient to yield 29mg (52%), MS m/e (%): 254 M + (100). According to the method described in Example 264 further pyridine derivatives were synthesised as intermediates for triazolo-pyridine derivatives. The results are compiled in the following list comprising example 265 to example 300. Example 301 2-(5-Bromo-furan-2-yl)-7-(3-chloro-phenyl)- [ 1,2,4] triazolo [ 1,5-a] pyridin-5-ylarnine To a solution of 28.7mg (O.llmmol) 4-(3-chloro-phenyl)-pyridine-2,6-diamine in 0.1 ml dioxane was added 26.7mg (0.12mmol) O-mesitylenesulfonylhydroxylamine (prepared from o-mesitylenesulfonylacetohydroxamate and HClO 4 (70%)) in 0.2ml dioxane at 5°C and kept there for lh. Upon warming to 50°C 25.1mg (0.14mmol) 5-bromo-2-furaldehyde in 0.25ml dioxane and 0.05ml 1M KOH in dioxane was added and stirred at 50°C over night (12h). The title compound was, after addition of formic acid, purified by reversed phase column chromatography eluting with an acetonitrile/water gradient to yield 6.7mg (15%), MS m/e (%): 389 M+H + (100). According to the method described in Example 301 further triazolo-pyridine derivatives were synthesised. The results are compiled in the following list comprising example 302 to example 314. Example 315 7- (5-Butyl-pyridin-2-yl)-2-furan-2-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-ylamine a) Mixture of (E)- and (Z)-3-(5-butyl-pyridin-2-yl)-acrylonitrile To a suspension of 1.66g (0.038mol) sodiumhydride (60% in oil) in 70 ml tetrahydrofiirane and 70 ml dimethylformamide were added 21.2g (0.063mol) (cyanomethyl)triphenylphosphonium chloride. After stirring for 1 hour at room temperature a solution of 6.83g (0.042mol) 5-butyl-2- pyridinecarboxaldehyde in 150 ml dioxane were added and stirring was continued for 15 hours. Then 40 ml methanol were added, the solvents were evaporated and the residue chromatographed on silicagel with ethylacetate/hexane 1/4 to yield 4.39g (56%) (E)/(Z)-3-(5-butyl-pyridin-2-yl)-acrylonitrile as an oil. MS m/e (%): 186 (M + , 47), 143 (100). b) 7-(5-Butyl-pyridin-2-yl)-2-furan-2-yl-f l,2,4ltriazolo[l,5-a1pyridin-5-ylamine The title compound, MS m/e (%): 334 (M+H + , 100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-furan-2-yl-lH- [1,2,4] triazole and (E)-3-(5-butyl-pyridin-2-yl)-acrylonitrile. Example 316 7- (2-Fluoro-pyridin-4-yl)-2-furan-2-yl- [ 1 ,2,4] triazolo [1,5-a] pyridin- 5-ylamine a) (E) and (Z)-3-(2-Fluoro-pyridin-4-yl)-acrylonitrile To a suspension of 2.80g (0.038mol) sodiumhydride (60% in oil) in 120 ml tetrahydrofiirane and 120 ml dimethylformamide were added 21.6g (0.064mol) (cyanomethyl)triphenylphosphonium chloride. After stirring for 1 hour at room temperature a solution of 4.00g (0.032mol) 2-fluoro-4-pyridinecarboxaldehyde in 35 ml tetrahydrofiirane were added and stirring was continued for 2 days. Then 30 ml methanol were added, the solvents were evaporated and the residue chromatographed on silicagel with ethylacetate/hexane 1/2 to yield 0.45g (10%) (E)-and (Z)-3-(2-fluoro-pyridin-4-yl)- acrylonitrile as light yellow solid. MS m/e (%): 148 (M + , 100), 128 (43). b) 7-(2-Fluoro-pyridin-4-yl)-2-furan-2-yl-f 1,2,41 triazolo! l,5-alpyridin-5-ylamine The title compound, MS m/e (%): 296 (M+H + , 100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-furan-2-yl-lH- [l,2,4]triazole and 3-(2-fluoro-pyridin-4-yl)-acrylonitrile. Example 317 7-(5-Chloro-pyri(iin-2-yl)-2-furan-2-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine a) ( E) -3 - ( 5-Chloro-pyridin-2-yl) -acrylonitrile To a suspension of 1.97g (0.045mol) sodiumhydride (60% in oil) in 60 ml tetrahydrofiirane and 60 ml dimethylformamide were added 15.25g (0.045mol) (cyanomethyl)triphenylphosphonium chloride. After stirring for 1 hour at room temperature a solution of 6.39g (0.045mol) 5-chloro-2-pyridinecarboxaldehyde in 25 ml tetrahydrofiirane were added and stirring was continued for 2 days. Then 15 ml methanol were added, the solvents were evaporated and the residue was chromatographed on aluminiumoxide with ethylacetate/hexane 3/7 to yield 4.09g (55%) (E)- 3-(5-chloro- pyridin-2-yl)-acrylonitrile as white solid. MS m/e (%): 164 (M + , 100), 137 (17), 113 (45). b) 7-(5-Chloro-pyridin-2-yl)-2-furan-2-yl-!l,2,4ltriazolo!l,5-a1pyridin-5-ylamine The title compound, MS m/e (%): 312 (M+H + , 100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-furan-2-yl-lH- [1,2,4] triazole and 3-(5-chloro-pyridin-2-yl)-acrylonitrile. Example 318 2-Furan-2-yl-7-(6-methoxy-pyridin-3-yl)-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine a) (E) and (Z)-3-(6-Methoxy-pyridin-3-yl)-acrylonitrile A mixture of 5.94g (0.03mol) 5-bromo-2-methoxypyridine, 2.38 ml (0.036 mol) acrylonitrile, 15.1 ml (0.108 mol) triethylamine and 0.42g (0.0006 mol) bis(triphenylphosphine)palladium-(II)chloride in 120 ml dimethylformamide were stirred at 120 °C for 48 hours. The mixture was extracted with saturated aqueous sodiumbicarbonate solution and dried with sodiumsulfate. Chromatography on silicagel with hexane/ ethylacetate 85/15 gave 2.47g (51%) (E)/(Z)-3-(6-methoxy-pyridin-3-yl)- acrylonitrile as a white solid. MS m/e (%): 160 (M + , 76), 159 (100), 131 (49). b) 2-Furan-2-yl-7-(6-methoxy-pyridin-3-yl)-! 1,2,41 triazolo !l,5-a]pyridin-5-ylamine The title compound, MS m/e (%): 307 (M + , 100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-furan-2-yl-lH- [1,2,4] triazole and 3-(6-methoxy-pyridin-2-yl)-acrylonitrile. Example 319 4- ( 5- Amino-2-fiιran-2-yl- [ 1 ,2,4] triazolo [1,5-a] yridin- 7-yl)-N-phenyl- benzenesulfonamide (69-0030) a) 4-(2-Cyano-vinyl)-N-phenyl-benzenesulfonamide A mixture of 2.88g (0.009mol) 4-bromo-N-phenyl- benzenesulfonamide, 0.59g (0.011 mol) acrylonitrile, 4.65 ml (0.033 mol) triethylamine and 129g (0.0002 mol) bis(triphenylphosphine)palladium(II)chloride in 50 ml dimethylformamide were stirred at 120 °C for 72 hours. The mixture was extracted with saturated aqueous sodiumbicarbonate solution and dried with sodiumsulfate. Chromatography on silicagel with hexane/ethylacetate 7/3 gave 1.73g (69%) (E)/(Z)- 4-(2-cyano-vinyl)-N-phenyl- benzenesulfonamide as a white solid. MS m/e (%):MS m/e (%): 283 (M-H " , 100). b) 4-(5-Amino-2-furan-2-yl-! 1,2,41 triazolo! l,5-alpyridin-7-yl)-N-phenyl- benzenesulfonamide The title compound, MS m/e (%): 430 (M-H " , 100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-furan-2-yl-lH- [ l,2,4]triazole and 4-(2-cyano-vinyl)-N-phenyl-benzenesulfonamide Example 320: 2-Furan-2-yl-7- [4- (4-methyl-piperazine- 1 -sulfonyl)-phenyl] - [ 1 ,2,4] triazolo [ 1 ,5- a] pyridin-5-ylamine a) 3- [4-(4-Methyl-piperazine-l-sulfonyl)-phenyl1 -acrylonitrile A mixture of 24. lg (0.068mol) l-[(4-bromophenyl)sulfonyl]-4-methyl- piperazine, 5.38 ml acrylonitrile, 18.9 ml (0.26 mol) triethylamine and 0.95g (0.001 mol) bis(triphenylphosphine)palladium(II)chloride in 380 ml dimethylformamide were stirred at 120 °C for 72 hours. The mixture was extracted with saturated aqueous sodiumbicarbonate solution and dried with sodiumsulfate. Chromatography on silicagel with dichloromethane/methanol 98/2 gave 15.2g (77%) (E)/(Z)- 3-[4-(4-methyl- piperazine-l-sulfonyl)-phenyl] -acrylonitrile as a light yellow solid. MS m/e (%): 292 (M+H + , 100). b) 2-Furan-2-yl-7-[4-(4-methyl-piperazine-l-sulfonyI)-phenyl1 -[1,2,41 triazolo[ 1,5- a] pyridin-5-ylamine The title compound, MS m/e (%): 439 (M+H + , 100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-furan-2-yl-lH- [ l,2,4]triazole and 3- [4-(4-methyl-piperazine-l-sulfonyl)-phenyl] -acrylonitrile. Example 321 2- (2,4-Difluoro-phenyl)-7-pyridin-4-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridm-5-ylamine a) 2,4-Difluoro-benzoic acid (l-amino-2-benzenesulfonyl-ethyIidene)-hydrazide A suspension of 15.3g (0.058mol) 2-(phenylsulfonyl)-ethanimidic acid ethyl ester hydrochloride in 125 ml chloroform was treated with 58.1 ml IN aqueous sodium hydoxide. 18 ml of a saturated aqueous sodiumbicarbonate solution was added and the mixture was extracted with chloroform. The extracts were combined and dried with sodium sulfate and the solvents were distilled off under reduced pressure. The resulting colorless oil was stirred together with lO.Og (0. 058mol) 2,4-difluorobenzoic acid hydrazide in 110ml chloroform over night at 50°C. The resulting precipitate was filtered off and dried. A yield of 8.50g (42%) 2,4-difluoro-benzoic acid ( l-amino-2-benzenesulfonyl- ethylidene) -hydrazide was obtained as white solid. MS m/e (%): 354 (M+H + , 100). b) 3-Benzenesulfonylmethyl-5-(2,4-difluoro-phenyl)-lH-! 1,2,41 triazole 8.0g (0.023mol) 2,4-Difluoro-benzoic acid (l-amino-2-benzenesulfonyl-ethylidene)- hydrazide were heated at 210°C for 20 minutes. The molten mass was then cooled, dissolved in 30 ml hot ethanol and stirred overnight at room temperature. The precipitated crystals were filtered off and dried to yield 5.35 g (71%) 3-benzenesulfonylmethyl-5-(2,4- difluoro-phenyl)-lH-[l,2,4]triazole as white solid, MS m/e (%): 336 (M+H + , 100). c 2-(2,4-Difluoro-phenyl)-7-pyridin-4-yl-f 1,2,41 triazolo [l,5-alpyridin-5-ylamine The title compound, MS m/e (%): 323 (M + , 100), 303 (60), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-(2,4-difluoro- phenyl)-lH-[l,2,4]triazole and (E)/(Z)-3-pyτidin-4-yl-acrylonitrile. Example 322 2-(2,4-Difluoro-phenyl)-7-pyridin-2-yl-[l,2,4]triazolo[l,5-a]pyridin- 5-ylamine The title compound, MS m/e (%):324(M+H + ,100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-(2,4-difluoro-phenyl)-lH- [1,2,4] triazole and (E)/(Z)-3-pyridin-2-yl-acrylonitrile. Example 323 2- (2-Fluoro-phenyl)-7-pyridin-4-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-ylamine a) 2-Fluoro-benzoic acid (l-amino-2-benzenesulfonyl-ethylidene)-hydrazide A suspension of 15.2g (0.058mol) 2-(phenylsulfonyl)-ethanimidic acid ethyl ester hydrochloride in 160 ml chloroform was treated with 57.7 ml IN aqueous sodium hydoxide. 80 ml of a saturated aqueous sodiumbicarbonate solution was added and the mixture was extracted with chloroform. The extracts were combined and dried with sodium sulfate and the solvents were distilled off under reduced pressure. The resulting colorless oil was stirred together with 9.98g (0. 063mol) 2-fluorobenzoic acid hydrazide in 65 ml chloroform over night at 50°C. The resulting precipitate was filtered off and dried. A yield of 14.6g 2-fluoro-benzoic acid (l-amino-2-benzenesulfonyl-ethylidene)-hydrazide was obtained as white solid. MS m/e (%): 336 (M+H + , 100). b) 3-Benzenesulfonylmethyl-5-(2-fluoro-phenyl)-lH-[l,2,4]triazole 14g (0.042mol) 2-fluoro-benzoic acid (l-amino-2-benzenesulfonyl-ethylidene)-hydrazide were heated at 210°C for 20 minutes. The molten mass was then cooled, dissolved in 40 ml hot ethanol and stirred overnight at room temperature. The precipitated crystals were filtered off and dried to yield 11.4 g (86%) 3-benzenesulfonylmethyl-5-(2-fluoro-phenyl)- lH-[l,2,4]triazole as beige solid, MS m/e (%): 317 (M + , 2), 253(68), 176(100), 122(61). c) 2-(2-Fluoro-phenyl)-7-pyridin-4-yl-[l,2,4]triazolo[l,5-alpyridin-5-ylamine The title compound, MS m/e (%):306(M+H + ,100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-(2-fluoro-phenyl)-lH- [1,2,4] triazole and (E)/(Z)-3-pyridin-4-yl-acrylonitrile. Example 324 2- (2-Fluoro-phenyl)-7-(6-methoxy-pyridin-3-yl)- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-ylamine The title compound, MS m/e (%):336(M+H + ,100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-(2-fluoro-phenyl)-lH- [ l,2,4]triazole and (E)/(Z)-3-(6-methoxy-pyridin-3-yl)-acrylonitrile. Example 325 7- (2-Ethyl-pyridin-4-yl)-2-pyridin-2-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin- 5-ylamine The title compound, MS m/e (%):316(M + ,100), was prepared in accordance with the general method of example 1 from 2-(5-benzenesulfonylmethyl-2H-[l,2,4]triazol-3-yl)- pyridine and (E)-3-(2-ethyl-pyridin-4-yl)-acrylonitrile. Example 326 7-(2-Memyl-pyridin-4-yl)-2-pyridin-2-yl-[l,2,4]triazolo[l,5-a]pyridin- 5-ylamine The title compound, MS m/e (%):303 (M+H + ,100), was prepared in accordance with the general method of example 1 from 2-(5-benzenesulfonylmethyl-2H-[l,2,4]triazol-3-yl)- pyridine and (E)/(Z)-3-(2-methyl-pyridin-4-yl)-acrylonitrile. Example 327 7- (5-Ethyl-pyridin-2-yl)-2-pyridin-2-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-ylamine a) (E)/(Z)-3-(5-Ethyl-pyridin-2-yl)-acrylonitrile (E)/(Z)-3-(5-Ethyl-pyridin-2-yl)-acrylonitrile was obtained from 5-ethyl-2- pyridinecarboxaldehyde and (cyanomethyl)triphenylphosphonium chloride /sodiumhydride in THF as a liqid, MS m/e (%):158(M + ,100). b) 7-(5-Ethyl-pyridin-2-yl)-2-pyridin-2-yl-[l,2,4]triazolo[l,5-a1pyridin-5-ylamine The title compound, MS m/e (%):317 (M+H + ,100), was prepared in accordance with the general method of example 1 from 2-(5-benzenesulfonylmethyl-2H-[l,2,4]triazol-3-yl)- pyridine and (E)/(Z)-3-(5-ethyl-pyridin-2-yl)-acrylonitrile. Example 328 2,7-Di-pyridin-2-yl- [ 1 ,2,4] triazolo [1,5-a] pyridin-5-ylamine The title compound, MS m/e (%):289 (M+H + ,100), was prepared in accordance with the general method of example 1 from 2-(5-benzenesulfonylmethyl-2H-[l,2,4]triazol-3-yl)- pyridine and (E)/(Z)-3-pyridin-2-yl-acrylonitrile. Example 329: 2-Pyridin-2-yl-7-pyridin-3-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-ylamine The title compound, MS m/e (%):288 (M + ,100), was prepared in accordance with the general method of example 1 from 2-(5-benzenesulfonylmethyl-2H-[ 1,2,4] triazol-3-yl)- pyridine and (E)/(Z)-3-pyridin-3-yl-acrylonitrile. Example 330 2-Pyridin-3-yl-7-pyridin-2-yl- [1,2,4] triazolo [ 1,5-a] pyridin-5-ylamine a) Nicotinic acid (l-amino-2-benzenesulfonyl-ethylidene)-hvdrazide A suspension of 23.6g (0.089mol) 2-(phenylsulfonyl)-ethanimidic acid ethyl ester hydrochloride in 300 ml chloroform was treated with 98 ml IN aqueous sodium hydoxide. 200 ml of a saturated aqueous sodiumbicarbonate solution was added and the mixture was extracted with chloroform. The extracts were combined and dried with sodium sulfate and the solvents were distilled off under reduced pressure. The resulting colorless oil was stirred together with 13.5g (0. 098mol) nicotinic acid hydrazide in 500ml dioxane over night at 50°C. The resulting precipitate was filtered off and dried. A yield of 15.5g (55%) nicotinic acid (l-amino-2-benzenesulfonyl-ethylidene)-hydrazide was obtained as white solid, MS m/e (%): 319 (M+H + , 100). b) 3-(5-Benzenesulfonylmethyl-2H-[ 1,2,41 triazol-3-yl)-pyridine 15.0g (0.047mol) nicotinic acid (l-amino-2-benzenesulfonyl-ethylidene) -hydrazide were heated at 220°C for 20 minutes. The molten mass was then cooled, dissolved in 100 ml hot ethanol and stirred overnight at room temperature. The precipitated crystals were filtered off and dried to yield 13.6 g (96%) 3-(5-benzenesulfonylmethyl-2H-[l,2,4]triazol-3-yl)- pyridine as white solid, MS m/e (%): 300 (M\ 8), 236(99), 159 (100), 105(43), 77(35). c) 2-Pyridin-3-yl-7-pyridin-2-yl-[ 1,2,4] triazolo [ 1,5-a] pyridin-5-ylamine The title compound, MS m/e (%):289 (M+H + ,100), was prepared in accordance with the general method of example 1 from 3-(5-benzenesulfonylmethyl-2H-[l,2,4]triazol-3-yl)- pyridine and (E)/(Z)-2-pyridin-2-yl-acrylonitrile. Example 331 7- (5-Chloro-pyridin-2-yl)-2-pyridin-2-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-ylamine a) 3-(5-Chloro-pyridin-2-yl)-acrylonitrile 3-(5-Chloro-pyridin-2-yl)-acrylonitrile was obtained from 5-chloro-picolinaldehyde and diethyl cyanomethyl-phosphonate/sodiumhydride in THF as a white solid, MS m/e (%):164(M + ,100), 137(17), 113(45). b) 7-(5-Cmoro-pyridin-2-yl)-2-pyridin-2-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine The title compound, MS m/e (%):323 (M+H + ,100), was prepared in accordance with the general method of example 1 from 2-(5-benzenesulfonylmethyl-2H-[l,2,4]triazol-3-yl)- pyridine and (E)/(Z)- 3-(5-chloro-pyridin-2-yl)-acrylonitrile. Example 332 7- (6-Chloro-pyridin-3-yl)-2-pyridin-2-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin- 5-ylamine The title compound, MS m/e (%):323 (M+H + ,100), was prepared in accordance with the general method of example 1 from 2-(5-benzenesulfonylmethyl-2H-[l,2,4]triazol-3-yl)- pyridine and (E)/(Z)- 3-(6-chloro-pyridin-3-yl)-acrylonitrile. Example 333 7-(6-Morpholin-4-yl-pyridin-3-yl)-2-pyridin-2-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine A solution of 0.10g (0.0003 mol) 7-(6-chloro-pyridin-3-yl)-2-pyridin-2-yl- [l,2,4]triazolo[l,5-a]pyridin-5-ylamine in 15 ml morpholine were stirred at 130°C for 4 hours. Removal of the amine and chromatography on silicagel with dichloromethane/methanol 9/1 gave 0.07g (62%) 7-(6-morpholin-4-yl-pyridin-3-yl)-2- pyridin-2-yl-[ 1,2,4] triazolo [ 1,5-a] pyridin-5-ylamine as beige solid, MS m/e (%):374 (M+H + ,100). Example 334 7- (6-Isopropylamino-pyridin-3-yl)-2-pyridin-2-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5- ylamine A solution of 0.16g (0.00035mol) 7-(6-chloro-pyridin-3-yl)-2-pyridin-2-yl- [ 1, 2,4] triazolo [ 1,5-a] pyridin-5-ylamine in 80 ml isopropylamine were stirred at 150°C for 150 hours in an autoclav. Removal of the amine and chromatography on silicagel with dichloromethane/methanol 9/1 gave 0.05g (29%) 7-(6-isopropylamino-pyridin-3-yl)-2- pyridin-2-yl- [1,2,4] triazolo [ 1,5-a] pyridin -5 -ylamine as beige solid, MS m/e (%):346 (M+H + ,100). Example 335 7-(6-Ethylam o-pyridm-3-yl)-2-pyridin-2-yl-[l,2,4]triazolo[l,5-a]pyridm-5-ylamine The title compound, MS m/e (%):331 (M + ,100). was prepared from 7-(6-chloro-pyridin- 3-yl)-2-pyridin-2-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine and ethylamine as described for the previous example 334. Example 336 7- (6-Chloro-pyridin-2-yl)-2-pyridin-2-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridm-5-ylamine a) E-3-(6-Chloro-pyridin-2-yl)-acrylonitrile E-3-(6-Chloro-pyridin-2-yl)-acrylonitrile was obtained from 6-chloro-2- pyridinecarboxaldehyde and diethyl cyanomethyl-phosphonate/sodiumhydride in THF as a white solid, MS m/e (%):164(M + ,100), 137(14), 113(75). b) 7-(6-Chloro-pyridin-2-yl)-2-pyridin-2-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine The title compound, MS m/e (%):323 (M+H + ,100), was prepared in accordance with the general method of example 1 from 2-(5-benzenesulfonylmethyl-2H-[l,2,4]triazol-3-yl)- pyridine and E-3-(6-chloro-pyridin-2-yl)-acrylonitrile. Example 337 7- (6-Ethylamino-pyridin-2-yl)-2-pyridin-2-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin- 5-ylamine The title compound, MS m/e (%):331 (M + ,100). was prepared from 7-(6-chloro-pyridin- 2-yl)-2-pyτidin-2-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine and ethylamine as described for the example 334. Example 338 2-Methylsulfanyl-7-pyridin-2-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-ylamine a) l-[[l-Amino-2-(phenylsulfonyl)efhylidene1 aminol-2-methyl-2-thiopseudourea (or tautomer) A suspension of 211g (0.80mol) 2-(phenylsulfonyl)-ethanimidic acid ethyl ester hydrochloride in 2 1 chloroform was treated with 801 ml IN aqueous sodium hydoxide. 350 ml of a saturated aqueous sodiumbicarbonate solution was added and the mixture was extracted with chloroform. The extracts were combined and dried with sodium sulfate and the solvents were distilled off under reduced pressure. The resulting oil was dissolved in 450 ml ethanol and the solution was added to a suspension of 44.6g (0.82mol) sodiummethylate and 187g (O.δOmol) methyl aminomethanehydrazonothioate hydroiodide. After 75 minutes at room temperature 4.8 1 of a 3/1 water/saturated aqueous sodiumbicarbonate solution was added and the mixture was extracted with chloroform. The organic phase was dried with sodiumsulfate and the solvents were evaporated. Recrystallisation from 1.8 1 ethanol gave 121 g (53%) l-[[l-amino-2- (phenylsulfonyl)ethylidene] amino] -2-methyl-2-thiopseudourea (or tautomer), MS m/e (%): 287 (M+H + , 100), 270 (28). b) 3-Benzenesulfonylmethyl-5-methylsulfanyl-lH-[l,2,4ltriazole 83.0g (0.29mol) l-[[l-Amino-2-(phenylsulfonyl)ethylidene]amino]-2-methyl-2- thiopseudourea in 830 ml IN HCl were refluxed for 30 minutes. After cooling the product crystallised. It was filtered off, washed with water and dried at 50°C/vacuum.Yield: 67.4g (86%), white solid with melting point 160-161°C. c) 2-Methylsulfanyl-7-pyridin-2-yl-[ 1,2,4] triazolo[l,5-alpyridin-5-ylamine The title compound, MS m/e (%):258 (M+H + ,100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmefhyl-5-methylsulfanyl-lH- [1,2,4] triazole and (E)/(Z)-3-pyridin-2-yl-acrylonitrile. Example 339 2-Pyrazol-l-yl-7-pyridin-2-yl- [1,2,4] triazolo [ 1,5-a] pyridin-5-ylarnine a) 2-Methanesulfinyl-7-pyridin-2-yl-[ 1,2,4] triazolo [ l,5-alpyridin-5-ylamine 8.66g (0.034mol) 2-Methylsulfanyl-7-pyridin-2-yl-[ 1,2,4] triazolo[l,5-a]pyridin-5-ylamine in 850 ml dichloromethane were oxidised with a solution of 17.6g (0.067mol) 3-phenyl-2- (phenylsulfonyl)oxaziridine in 150 ml dichloromethane overnight. Chromatography on aluminiumoxide (dichloromethane/ methanol 97:3) and on silicagel (ethylacetate/ methanol 9:1) yielded 5.2g (57%) 2-methanesulfinyl-7-pyτidin-2-yl-[ 1,2,4] triazolo [ 1,5- a]pyridin-5-ylamine, MS m/e (%):274 (M+H + ,100). b) 2-Pyrazol-l-yl-7-pyridin-2-yl-[l,2,4ltriazolo[l,5-alpyridin-5-ylamine A mixture of 0.50g (0.002mol) 2-methanesulfinyl-7-pyridin-2-yl-[l,2,4]triazolo[l,5- a]pyridin-5-ylamine and 0.33ml (0.002 mol) 1,8-diazabicyclo [5.4.0] undec-7-en in 12.5 g molten pyrazole as solvent was stirred overnight at 120°C. Destination of the solvent and chromatography on silicagel with ethylacetate/ methanol 95/5 gave 0.13g (26%) 2-pyrazol- l-yl-7-pyridin-2-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine as a white solid, MS m/e (%):278 (M+H + ,100). Example 340 7-Pyridin-2-yl-2- [ 1 ,2,4] triazol- 1-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin- 5-ylamine The title compound, MS m/e (%):279 (M+H + ,100), was prepared in accordance with the method of example 339b) from 2-methanesulfinyl-7-pyridin-2-yl-[ 1,2,4] triazolo [1,5- a]pyridin-5-ylamine and l,8-diazabicyclo[5.4.0]undec-7-en in 1,2,4-triazole at 130°C. Example 341 2-(2-Methyl-imidazol-l-yl)-7-pyridin-2-yl-[l,2,4]triazolo[l,5-a]pyrid -5-ylarnine The title compound, MS m/e (%):292 (M+H + ,100), was prepared in accordance with the method of example 339b) from 2-methanesulfinyl-7-pyridin-2-yl-[ 1,2,4] triazolo [1,5- a]pyridin-5-ylamine and 1, 8-diazabicyclo[ 5.4.0] undec-7-en in 2-methylimidazole at 170°C. Example 342 2-Phenethyloxy-7-pyridin-2-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine 0.06 g (0.003mol) sodium in 50 ml 2-phenylethanol were stirred overnight at 60°C. 0.2g (0.0007mol) 2-methanesulfinyl-7-pyridin-2-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine were added and stirring was continued at 160°C for 16 hours. Evaporation of the solvent and chromatography on silicagel with ethylacetate gave 0.2g (83%) 2-phenethyloxy-7- pyridin-2-yl-[ 1,2,4] triazolo [ 1,5-a] pyridin-5-ylamine, MS m/e (%):332 (M+H + ,100). Example 343 2-Pyridin-2-yl-7-thiophen-3-yl- [ 1 ,2,4] triazolo [1,5-a] pyridin-5-ylamine The title compound, MS m/e (%):294 (M+H + ,100). was prepared according to the procedure of example 92 from 7-bromo-2-pyridin-2-yl-[ 1,2,4] triazolo [1,5-a] pyridin-5- ylamine and 3-thiophenboronic acid. Example 344 2-Pyrazol- 1 -yl-7-pyridin-3-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-ylamine a) 2-Methylsulfanyl-7-pyridin-3-yl-[ 1,2,41 triazolo [ 1,5-a] pyridin-5-ylamine 2-Methylsulfanyl-7-pyridin-3-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, a white solid with melting point 161-163°C, was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-methylsulfanyl-lH-[l,2,4]triazole and (E)/(Z)-3-pyridin-3-yl-acrylonitrile. b) 2-Methanesulfinyl-7-pyridin-3-yl-[ 1,2,4] triazolo [l,5-alpyridin-5-ylamine 2-Methanesulfinyl-7-pyridin-3-yl-[ 1,2,4] triazolo[l,5-a]pyridin-5-ylamine, MS m/e (%):274 (M+H + ,100), was prepared in accordance with the method of example 339a) from 2-methylsulfanyl-7-pyridin-3-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine and 3- phenyl-2-(phenylsulfonyl)oxaziridine. c) 2-Pyrazol-l-yl-7-pyridin-3-yl-[l,2,4ltriazolo[l,5-a]pyridin-5-ylamine The title compound, MS m/e (%):277 (M + ,100), was prepared in accordance with the method of example 339b) from 2-methanesulfinyl-7-pyridin-3-yl-[l,2,4]triazolo[l,5- a]pyridin-5-ylamine and l,8-diazabicyclo[5.4.0]undec-7-en in pyrazole at 75°C. Example 345 8-Benzenesulfonyl-2-furan-2-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine The title compound, MS m/e (%): 341 (M+H + , 100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-furan-2-yl-lH- [1,2,4] triazole and 3-methoxy-2-propenitrile. Example 346 8-Benzenesulfonyl-2-pyridin-2-yl- [ 1 ,2,4] triazolo [ 1 ,5-a]pyridin-5-ylamine The title compound, MS m/e (%): 351 (M + , 92), 286(100), 171(54), was prepared in accordance with the general method of example 1 from 2-(5-benzenesulfonylmethyl-2H- [l,2,4]triazol-3-yl)-pyridine and 3-methoxy-2-propenitrile. Example 347 5-Amino-2-phenyl- [ 1 ,2,4] triazolo [1,5-a] pyridine-8-carbonitrile The title compound, MS m/e (%): 235 (M + , 100), 208(10), 104(16), was prepared in accordance with the general method of example 1 from (5-phenyl-2H-[l,2,4]triazol-3-yl)- acetonitrile and 3-methoxy-2-propenitrile. Example 348 2- [ 1 - (2,7-Di-pyridin-2-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin- 5-yl)- 1 ,4,5,6-tetrahydro- pyrimidin-2-yl]-benzoic acid The title compound, MS m/e (%): 476 (M+H + , 100), was prepared in accordance with the general method of example 27 from 2,7-di-pyτidin-2-yl-[l,2,4]triazolo[l,5-a]pyridin-5- ylamine and N-(3-bromopropyl)-phthalimide. Example 349 7- (5-Methoxy-pyridin-2-yl)-2-pyridin-2-yl- [ 1 ,2,4] triazolo [1,5-a] pyridm-5-ylaιnine a) (E) and (Z)-3-(5-Methoxy-pyridin-2-yl)-acrylonitrile To a suspension of 1.60 g (0.036 mol) sodiumhydride (55% in oil) in 70 ml tetrahydrofurane and 50 ml dimethylformamide were added 12.32 g (0.036mol) (cyanomethyl)triphenylphosphonium chloride. After sirring for 1 hour at room temperature a solution of 6.39g (0.045mol) 5-chloro-2-pyridinecarboxaldehyde in 25 ml tetrahydrofurane were added and stirring was continued for 1 day. Then 100 ml water were added. It has been extracted three times with ethyl acetate and the organic phase was dried over sodium sulfate. The solvents were evaporated and the residue was chromatographed on silica gel with ethylacetate/hexane 1/4 to yield 4.90 g (65%) 3-(5-methoxy-pyridin-2- yl) -acrylonitrile (E/Z = 2/5) as a yellow oil. MS m/e (%): 160 (M + , 100), 109 (34), 90 (36). b) 7-(5-Methoxy-pyridin-2-yl)-2-pyridin-2-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine The title compound, Mp.: 227-228° C, was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-pyridin-2-yl-lH-[l,2,4]triazole and 3-(5-methoxy-pyridin-2-yl)-acrylonitrile. Example 350 7-Morpholin-4-yl-2-pyridin-2-yl- [ 1 ,2,4] triazolo [ 1,5-a] pyridin-5-ylamine 7-Bromo-2-pyridin-2-yl-[ 1,2,4] triazolo [ 1,5-a] pyridin-5-ylamine (50 mg, 0.17 mmol) were dissolved in 2 ml of morpholin and heated to 180° C for 16 h. Excess morpholin has been evaporated and the residue was partitioned between water and methylene chloride (10 ml each). The inorganic phase has been extracted twice with methylene chloride (10 ml) and the combined organic phases were dried over sodium sulfate. The filtrate has been evaporated and the residue was crystallized from dichloromethane to yield 7-morpholin-4- yl-2-pyridin-2-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine (33 mg, 65 %) as a white solid; M.p.: 240-241° C. Example 351 7- (4-Methyl-piperazin- 1 -yl)-2-pyridin-2-yl- [ 1 ,2,4] triazolo [1,5-a] pyridin-5-ylamine 7-Bromo-2-pyridin-2-yl-[ 1,2,4] triazolo [ 1,5-a] pyridin-5-ylamine (15 mg, 0.05 mmol) were dissolved in 2 ml of N-methyl-piperazin and heated to 180° C for 16 h. Excess N-methyl- piperazin has been evaporated and the residue was partitioned between water and ethyl acetate (10 ml each). The inorganic phase has been extracted twice with methylene chloride ( 10 ml) and the combined organic phases were dried over sodium sulfate. The filtrate has been evaporated and the residue was subjected to column chromatography on silica gel with ethyl acetate, then dichloromethane/methanol 9/1 and eventually dichloromethane/methanol 4/1 as eluents to yield 7-(4-methyl-piperazin-l-yl)-2-pyridin- 2-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine (5.0 mg, 31 %) as a yellow solid. MS: (ISP) m/e 332 (M+Na + , 25 %), 310 (M+H + , 100 %).

Claims: Claims 1. A compound of the general formula wherein R 1 is a 5 or 6 membered heteroaryl group, containing 1 to 3 heteroatoms, selected from N, O or S, and which groups are optionally substituted by one or two substituents, which are lower alkyl, -(CH 2 ) n OH, halogen or lower alkoxy, and wherein the heteroaryl groups may be optionally linked to the pyrazole ring via an alkylene or alkenyle group, or is phenyl, optionally substituted by one or two substituents being lower alkyl, hydroxy-lower alkyl, halogen, hydroxy or lower alkoxy or is -O(CH 2 ) n phenyl, benzofuryl, indolyl or benzothiophenyl, or is -S-lower alkyl; R 2 and R 4 are independently from each other hydrogen, cyano or -S(O) 2 -phenyl; R 3 is hydrogen, halogen or is a 5 or 6 membered heteroaryl group, containing 1 to 3 heteroatoms, selected from N, O or S, and which groups are optionally substituted by one or two substituents, which are lower alkyl, -(CH 2 ) n -aryl, hydroxy, halogen, lower alkoxy, morphohnyl, amino, lower alkylamino or -C(O)NR' 2 , and wherein R' is lower alkyl or hydrogen, or is phenyl, optionally substituted by one or two substituents being halogen, lower alkyl, lower alkoxy, amino, di-lower alkyl amino, CF 3 , -OCF 3 , -NHC(O)lower alkyl, cyano, -C(O)-lower alkyl, -C(O)O-lower alkyl, -S-lower alkyl, -S(O) 2 NH-phenyl, -S(O) 2 -methylpiperazinyl; or is -NR'R", wherein R' and R" are independently from each other hydrogen, -(CH 2 ) n phenyl, which phenyl ring is optionally substituted by halogen or lower alkoxy, -CH(lower alkyl) -phenyl, indan-1-yl, 1,2,3,4-tetrahydro-naphthalen, or cycloalkyl; or is -O-phenyl, which phenyl ring is optionally substituted by halogen, lower alkyl or lower alkoxy, -O-tetrahydronaphthalenyl or -O-CH 2 -6-methyl-pyridin-2-yl; or is -benzo[ l,3]dioxolyl, -lH-indol-5-yl, naphthyl, benzofuran-2-yl, l,3,4,9-tetrahydro-b-carbolin-2-yl, piperidin-1-yl, pyrrolidin-1-yl, piperazin-4-yl-methyl or morphohnyl; R 5 is -NR 2 , wherein R may be the same or different and is hydrogen, lower alkyl, phenyl, benzyl, -CO-lower alkyl, -CO-lower alkoxy, -lower alkenyl, -CO(CH 2 ) n -phenyl or -COO(CH 2 ) n -phenyl, wherein the phenyl ring is optionally substituted by CF 3 , lower alkoxy, halogen or lower alkyl, -CO(CH 2 ) 3 -NHCO-lower alkoxy, -(CH 2 ) n -phenyl, wherein the phenyl ring is optionally substituted by lower alkoxy, CF 3 or halogen, or is 4,5-dihydro-lH-imidazol-2-yl-benzoic acid, l,4,5,6-tetrahydro-pyrimidin-2-yl-benzoic acid or 4,5,6,7-tetrahydro-lH-[l,3]diazepin-2-yl-benzoic acid; n is 0 - 4 and their pharmaceutically acceptable salts. 2. A compound of formula I, wherein R 1 is fur-2yl, lower alkenyl-fur-2-yl, benzofur-2yl, thiophen-2yl, thiazol-2yl, pyrrol- 2yl, pyridin-2yl, pyridin-4yl, tetrahydrofuran-2yl, lH-indol-3yl or phenyl, optionally substituted by one or two substituents being lower alkyl, hydroxy-lower alkyl, halogen, hydroxy or lower alkoxy; R 2 and R 4 are independently from each other hydrogen or cyano; R 3 is hydrogen, halogen, pyridin-4yl, pyridin-3yl, pyridin-2yl, optionally substituted by lower alkyl, halogen or an oxy group; or phenyl, optionally substituted by halogen or CF 3 ; R 5 is -NR 2 , wherein R may be the same or different and is hydrogen, lower alkyl, phenyl, benzyl, -CO-lower alkyl, -CO-lower alkoxy, -lower alkenyl, -CO(CH 2 ) n -phenyl or -COO(CH 2 ) n -phenyl, wherein the phenyl ring is optionally substituted by CF 3 , lower alkoxy, halogen or lower alkyl, -CO(CH 2 ) 3 -NHCO-lower alkoxy, -(CH 2 ) n -phenyl, wherein the phenyl ring is optionally substituted by lower alkoxy, CF 3 or halogen, or -(CH 2 ) n -isoindole-l,3-dione; R is hydrogen, lower alkyl, phenyl or benzyl and n is 0 - 4 and their pharmaceutically acceptable salts. 3. A compound according to claim 1, wherein R 5 is an unsubstituted amino group. 4. A compound according to claim 3, wherein R 1 is furyl. 5. A compound according to claim 4, which is 2-furan-2-yl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 2-furan-2-yl-7-pyridin-3-yl-[ 1,2,4] triazolo [ 1,5-a] pyridin-5-ylamine, 2-furan-2-yl-7-pyridin-2-yl-[ 1,2,4] triazolo [ 1,5-a] pyridin-5-ylamine, 7-(3,5-bis-trifluoromethyl-phenyl)-2-furan-2-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 7-(3,5-dichloro-phenyl)-2-furan-2-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 7-(4-chloro-phenyl)-2-furan-2-yl-[ 1,2,4] triazolo [ 1,5-a] pyridin-5-ylamine, 2-furan-2-yl-7-(2-methyl-pyridin-4-yl)-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 7-(2-ethyl-pyridin-4-yl)-2-furan-2-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 2-furan-2-yl-7-(2-propyl-pyridin-4-yl)-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 2-furan-2-yl-7-(2-isopropyl-pyridin-4-yl)-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 7-(4-fluoro-phenyl)-2-furan-2-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 2-furan-2-yl-7-(l-oxy-pyridin-4-yl)-[l ) 2,4]triazolo[l,5-a]pyridin-5-ylamine, 5-amino-2-furan-2-yl-7-pyridin-4-yl-[ 1,2,4] triazolo [l,5-a]pyridine-6-carbonitrile, 7-(3-amino-phenyl)-2-furan-2-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 7-(3,4-dimethoxy-phenyl)-2-furan-2-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 7-(3,4-dichloro-phenyl)-2-furan-2-yl-[ 1,2,4] triazolo[l,5-a]pyridin-5-ylamine, 7-(3-fluoro-phenyl)-2-furan-2-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, l-[3-(5-amino-2-furan-2-yl-[l,2,4]triazolo[l,5-a]pyridin-7-yl)-phenyl]-efhanone, 7-(2-fluoro-phenyl)-2-furan-2-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 2-furan-2-yl-7-m-tolyl-[ 1,2,4] triazolo [ 1,5-a] pyridin-5-ylamine, -furan-2-yl-7-(4-methylsulfanyl-phenyl)-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 2-furan-2-yl-7-thiophen-3-yl-[ 1,2,4] triazolo[ 1,5-a] pyridin-5-ylamine, 2-furan-2-yl-7-(3-trifluoromethyl-phenyl)-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 2-furan-2-yl-7-(3-methoxy-phenyl)-[ 1,2,4] triazolo [l,5-a]pyridin-5-ylamine, N-[3-(5-amino-2-furan-2-yl-[l,2,4]triazolo[l,5-a]pyridin-7-yl)-phenyl]-acetamide, 2-furan-2-yl-7-(lH-indol-5-yl)-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, N-[4-(5-amino-2-furan-2-yl-[ 1,2,4] triazolo[l,5-a]pyridin-7-yl)-2-methyl-phenyl]- acetamide, 2-furan-2-yl-7-piperidin- 1 -yl- [ 1 ,2,4] triazolo [ 1 ,5-a]pyridin-5-ylamine, 2-furan-2-yl-7-pyrrolidin-l-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 2-furan-2-yl-7-(4-methyl-piperazin-l-yl)-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, N7-(2-chloro-benzyl)-2-furan-2-yl-[l,2,4]triazolo[l,5-a]pyridine-5,7-diamine, 2-furan-2-yl-N7-(2-methoxy-benzyl)-[ 1,2,4] triazolo [ 1,5-a] pyridine-5,7-diamine, 2-furan-2-yl-N7-(l-phenyl-ethyl)-[l,2,4]triazolo[l,5-a]pyridine-5,7-diamine, 7-(5-butyl-pyτidin-2-yl)-2-furan-2-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 7-(2-fluoro-pyridin-4-yl)-2-furan-2-yl-[ l ) 2,4]triazolo[l,5-a]pyridin-5-ylamine, 7-(5-chloro-pyridin-2-yl)-2-furan-2-yl-[ 1,2,4] triazolo [ 1,5-a] pyridin-5-ylamine or 2-furan-2-yl-7-(6-methoxy-pyridin-3-yl)-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine. 6. A compound according to claim 3, wherein R 1 is methyl substituted furyl. 7. A compound according to claim 6, which is 7-(4-chloro-phenyl)-2-(5-methyl-furan-2-yl)-[ 1,2,4] triazolo[l,5-a]pyridin-5-ylamine, 7-(3-me oxy-phenyl)-2-(5-methyl-furan-2-yl)-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 7-(3,4-dimethoxy-phenyl)-2-(5-methyl-furan-2-yl)-[ 1,2,4] triazolo [ 1,5-a] pyτidin-5- ylamine, N-{3-[5-amino-2-(5-methyl-furan-2-yl)-[l,2,4]triazolo[l,5-a]pyridin-7-yl]-phenyl}- acetamide or N-{4-[5-amino-2-(5-methyl-furan-2-yl)-[l,2,4]triazolo[l,5-a]pyridin-7-yl]-phenyl}- acetamide. 8. A compound according to claim 3, wherein R 1 is pyridin-2-yl. 9. A compound according to claim 8, which is 7-(4-fluoro-phenyl)-2-pyridin-2-yl-[ 1,2,4] triazolo [ 1,5-a] pyridin-5-ylamine, 7-(3-methoxy-phenyl)-2-pyridin-2-yl-[ 1,2,4] triazolo[l,5-a]pyridin-5-ylamine, 7-(3-amino-phenyl)-2-pyridin-2-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 7-(2-ethyl-pyridin-4-yl)-2-pyridin-2-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 7-(2-methyl-pyridin-4-yl)-2-pyridin-2-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 7-(5-ethyl-pyridin-2-yl)-2-pyridin-2-yl-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 2,7-di-pyridin-2-yl- [ 1 ,2,4] triazolo [ 1 ,5-a] pyridin-5-ylamine, 7-(5-chloro-pyridin-2-yl)-2-pyridin-2-yl- [ 1,2,4] triazolo [ 1,5-a] pyridin-5-ylamine or 7- (6-chloro-pyridin-2-yl) -2-pyridin-2-yl- [ 1,2,4] triazolo [ 1,5-a] pyridin-5-ylamine. 10. A compound according to claim 3, wherein R 1 is 5,6-dihydro-furan-2-yl. 11. A compound according to claim 10, which is 7-(3,4-dichloro-phenyl)-2-(4,5-dihydro-furan-2-yl)-[l,2,4]triazolo[l,5-a]pyridin-5- ylamine, 2-(4,5-dihydro-furan-2-yl)-7-(3-fluoro-phenyl)-[l,2,4]triazolo[l,5-a]pyridin-5-ylamine, 2-(4,5-dihydro-furan-2-yl)-7-(4-fluoro-phenyl)-[ 1,2,4] triazolo [1,5-a] pyridin- 5-ylamine, 2-(4,5-dihydro-furan-2-yl)-7-m-tolyl-[ 1,2, 4] triazolo [ 1,5-a] pyridin-5-ylamine or 2-(4,5-dihydro-furan-2-yl)-7-(3-trifluoromethyl-phenyl)-[l,2,4]triazolo[l,5-a]pyridin-5- ylamine. 12. A compound according to claim 3, wherein R 1 is pyrazol-1-yl. 13. A compound according to claim 12, which is 2-pyrazol-l-yl-7-pyridin-2-yl- [ 1,2,4] triazolo [ l,5-a]pyridin-5-ylamine. 14. A compound according to claim 1, wherein R 5 is a substituted amino group. 15. A compound according to claim 14, wherein R 1 is phenyl. 16. A compound according to claim 15, which is but-3-enyl-(2-phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin-5-yl)-amine, ethyl- (2-phenyl-7-pyridin-4-yl-[ 1,2,4] triazolo[ 1,5-a] pyridin-5-yl)-amine, (2-phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin-5-yl)-carbamic acid ethyl ester, N-(2-phenyl-7-pyridin-4-yl-[ 1,2,4] triazolo [1,5-a] pyridin-5-yl)-4-trifluoromethyl- benzamide, 2-(2-chloro-phenyl)-N-(2-phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin-5-yl)- acetamide, 2-(2,4-dichloro-phenyl)-N-(2-phenyl-7-pyridin-4-yl-[ 1,2,4] triazolo[l,5-a]pyridin-5-yl)- acetamide, N-(2-phenyl-7-pyridin-4-yl-[ 1,2,4] triazolo[l,5-a]pyridin-5-yl)-2-(2-trifluoromethyl- phenyl)-acetamide, N-(2-phenyl-7-pyridin-4-yl-[ 1,2,4] triazolo[l,5-a]pyridin-5-yl)-2-(4-trifluoromethyl- phenyl)-acetamide, 3-phenyl-N-(2-phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin-5-yl)-propionamide, N-(2-phenyl-7-pyridin-4-yl- [ 1,2, 4] triazolo [ l,5-a]pyridin-5-yl)-2-o-tolyl-acetamide, 2-(2-bromo-phenyl)-N-(2-phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin-5-yl)- acetamide, 2-(2-iodo-phenyl)-N-(2-phenyl-7-pyridin-4-yl-[ 1,2,4] triazolo [ 1,5-a] pyridin-5-yl)- acetamide, 3-(2-phenyl-7-pyridin-4-yl-[ 1,2,4] triazolof l,5-a]pyridin-5-ylcarbamoyl)-propyl]- carbamic acid tert-butyl ester, 2-(2-chloro-phenyl)-ethyl]-(2-phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin-5-yl)- amine, 2-(2,4-dichloro-phenyl)-ethyl]-(2-phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin-5- yl)-amine, (2-phenyl-7-pyridin-4-yl-[ 1,2,4] triazolo[l,5-a]pyridin-5-yl)-(4-trifluoromethyl-benzyl)- amine, (3-phenyl-propyl)-(2-phenyl-7-pyri din-4-yl-[ 1,2,4] triazolo[l,5-a]pyridin-5-yl)-amine or diefhyl-(2-phenyl-7-pyridin-4-yl-[l,2,4]triazolo[l,5-a]pyridin-5-yl)-amine. 17. A medicament containing one or more compounds as claimed in any one of claims 1 - 16 and pharmaceutically acceptable excipients. 18. A medicament according to claim 17 for the treatment of diseases related to the adenosine receptor. 19. A process for preparing a compound of formula I as defined in claim 1, which process comprises a) reacting a compound of formula with a compound of formula to a compound of formula wherein R 1 - R 4 have the significances given in claim 1, or b) substituting one or two hydrogen atoms of the amino group in formula I-l by R, which is lower alkyl, phenyl, benzyl, -CO-lower alkyl, -CO-lower alkoxy, -lower alkenyl, - CO(CH 2 ) n -phenyl or -COO(CH 2 ) n -phenyl, wherein the phenyl ring is optionally substituted by CF 3 , lower alkoxy, halogen or lower alkyl, -CO(CH 2 ) 3 -NHCO-lower alkoxy, -(CH 2 ) n -phenyl, wherein the phenyl ring is optionally substituted by lower alkoxy, CF 3 or halogen, or c) reacting a compound of formula with a compound of formula R 3 B(OH) 2 V to a compound of formula I-l, wherein R 1 - R 4 have the significances given in claim 1, or d) modifying one or more substituents R 1 - R° within the definitions given above, and if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts. 20. A compound according to any one of claims 1 - 16, whenever prepared by a process as claimed in claim 18 or by an equivalent method. 21. The use of a compound in any one of claims 1 - 16 for the treatment of diseases related to the adenosine receptor or for the manufacture of corresponding medicaments. 22. The use of a compound in any one of claims 1 - 16 for the manufacture of corresponding medicaments for the treatment of diseases related to the adenosine A 2A receptor. 23. The invention as hereinbefore described.

Inventors: HUBER TROTTMANN GERDA, HUNKELER WALTER, JAKOB-ROETNE ROLAND, KILPATRICK GAVIN JOHN, NETTEKOVEN MATTHIAS HEINRICH, RIEMER CLAUS, HUBER TROTTMANN, GERDA, HUNKELER, WALTER, JAKOB-ROETNE, ROLAND, KILPATRICK, GAVIN, JOHN, NETTEKOVEN, MATTHIAS, HEINRICH, RIEMER, CLAUS
Applicants: HOFFMANN LA ROCHE, F. HOFFMANN-LA ROCHE AG
Application year: 2000
Main classification: C07D471
IPC codes: A61K31, A61P9, A61P11, A61P25, A61P37, A61P43, C07D213, C07D409, C07D471, C07D519